Steven M. Kornblau, MD

Peer-Reviewed Articles

1. Mosialou I, Al AM, Labella R, Bisikirska B, Cuesta-Dominguez A, Vgenopoulou P, Reyes I, Rao SM, Wang A, Luo N, Galan-Diez M, Zhao J, Chernak BJ, Bewersdorf JP, Fukasawa K, Su J, Higa J, Adams RA, Corper AL, Pampou S, Woods CM, Fan X, Shah RP, Liu J, Liu N, Liang C, Heiblig M, Kornblau SM, Garcia-Manero G, Berman E, Jurcic JG, Rabadan R, Raza A, Kousteni S. A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies, 2025.
2. Escherich, CS, Moriyama, T, Li, Z, Hsiao, YC, Yang, W, Li, Y, Reyes, N, Walker, M, Budhraja, A, Bhatara, S, Diaz-Flores, E, Stock, W, Paietta, E, Konopleva, M, Kornblau, SM, Litzow, M, Inaba, H, Pui, CH, Opferman, JT, Loh, ML, Yu, J, O'Brien, MM, Evans, W, Yang, JJ. DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood 145(11):1182-1194, 2025. e-Pub 2025. PMID: 39791601.
3. Mamdouh AM, Lim FQ, Mi Y, Olesinski EA, Chan CGT, Jasdanwala S, Lin XX, Wang Y, Tan JYM, Bhatia KS, Sapozhnikova V, Wang C, Mahesh AN, Liang DTE, Chitkara N, Mertins P, Hogdal L, Brown BD, Haferlach T, Lobry C, Lindsley C, Puissant A, Ho HK, Das S, Letai A, Kornblau SM, Krönke J, Ayoub E, Itahana K, Andreef M, Bhatt S. Targetable BIRC5 dependency in therapy-resistant TP53 mutated acute myeloid leukemia. e-Pub 2025.
4. Kornblau SM, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1):e35662, 2025. e-Pub 2024. PMID: 39584789.
5. Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yoshimura S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun 15(1):3681, 2024. e-Pub 2024. PMID: 38693155.
6. Hoff, FW, Sriraja, L, Qiu, Y, Jenkins, GN, Teachey, DT, Wood, B, Devidas, M, Shockley, S, Loh, ML, Petsalaki, E, Kornblau, SM, Horton, T. The Proteomics of T-Cell and Early T-Cell Precursor (ETP) Acute Lymphocytic Leukemia. Cancers 16(24), 2024. e-Pub 2024. PMID: 39766140.
7. Yoshimura S, Li Z, Gocho Y, Yang W, Crews KR, Lee SHR, Roberts KG, Mullighan CG, Relling MV, Yu J, Yeoh AEJ, Loh ML, Saygin C, Litzow MR, Jeha S, Karol SE, Inaba H, Pui CH, Konopleva M, Jain N, Stock W, Paietta E, Jabbour E, Kornblau SM, Evans WE, Yang JJ. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 42(29):3478-3490, 2024. e-Pub 2024. PMID: 39102629.
8. DiNardo, C, Verma, D, Baran, N, Bhagat, TD, Skwarska, A, Lodi, A, Saxena, K, Cai, T, Su, X, Guerra, VA, Poigaialwar, G, Kuruvilla, VM, Konoplev, S, Gordon-Mitchell, S, Pradhan, K, Alluri, S, Hackman, GL, Chaudhry, S, Collins, M, Sweeney, SR, Busquets, J, Rathore, AS, Deng, Q, Green, M, Grant, S, Demo, SD, Choudhary, GS, Sahu, S, Agarwal, B, Spodek, M, Thiruthuvanathan, V, Will, B, Steidl, U, Tippett, G, Burger, JA, Borthakur, G, Jabbour, EJ, Pemmaraju, N, Kadia, TM, Kornblau, SM, Daver, N, Naqvi, K, Short, NJ, Garcia-Manero, G, Tiziani, S, Verma, A, Konopleva, M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes. Nature Cancer 5(10):1515-1533, 2024. e-Pub 2024. PMID: 39300320.
9. Kornblau SM. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: A phase Ib/II clinical trial and correlative analyses. Nature Cancer, 2024. PMID: 36865338.
10. Marvin-Peek J, Sasaki K, Kontoyiannis DP, Adachi J, Ohanian M, Takahashi K, Issa GC, Kornblau S, Abbas HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series. Front Med (Lausanne) 11:1402897, 2024. e-Pub 2024. PMID: 39149601.
11. Narayanan N, Marvin-Peek J, Abouelnaaj MK, Majid D, Wang B, Brown BD, Qiu Y, Kornblau SM, Abbas HA. Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia. J Proteome Res 23(7):2495-2504, 2024. e-Pub 2024. PMID: 38829961.
12. de Camargo Magalhães ES, Hubner SE, Brown BD, Qiu Y, Kornblau SM. Proteomics for Optimizing Therapy in Acute Myeloid Leukemia: Venetoclax plus Hypomethylating Agents versus Conventional Chemotherapy. Leukemia 38(5):1046-1056, 2024. e-Pub 2024. PMID: 38531950.
13. Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell 42(4):552-567.e6, 2024. e-Pub 2024. PMID: 38593781.
14. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
15. van Dijk AD, Hoff FW, Qiu Y, Hubner SE, Go RL, Ruvolo VR, Leonti AR, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, ESJM DB, Horton TM, Kornblau SM. Chromatin Profiles are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 trial. Cancers (Basel) 16(8), 2024. e-Pub 2024. PMID: 38672531.
16. Yang J, Escherich C, Li Z, Barnett K, Li Y, Walker M, Yang W, Huang X, Yu J, Stock W, Paietta E, Konopleva M, Kornblau S, Jabbour E, Litzow M, Inaba H, C-H P, Loh M, Evans W, Savic D. Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin. NatCancer, 2024. e-Pub 2024.
17. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. A phase 2 study of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukemia. The Lancet Oncology, 2024. PMID: 38452788.
18. Bose P, Masarova L, Pemmaraju N, Bledsoe Soboyejo SD, Daver N, Jabbour E, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes J, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SD, Zhou L, Pierce SA, Wang X, Pike A, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for Anemia of Myelofibrosis: a Phase 2 Investigator-initiated Study. Cancer, 2024. PMID: 38572554.
19. Marvin-Peek, J, Sasaki, K, Kontoyiannis, DP, Adachi, JA, Ohanian, M, Takahashi, K, Issa, GC, Kornblau, SM, Abbas, HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia. Frontiers in Medicine 11, 2024. e-Pub 2024. PMID: 39149601.
20. Kimura S, Park CS, Montefiori LE, Iacobucci I, Polonen P, Gao Q, Arnold ED, Attarbaschi A, Brown A, Buldini B, Caldwell KJ, Chang Y, Chen C, Cheng C, Cheng Z, Choi J, Conter V, Crews KR, de Groot-Kruseman HA, Deguchi T, Eguchi M, Muhle HE, Elitzur S, Escherich G, Freeman BB, Gu Z, Han K, Horibe K, Imamura T, Jeha S, Kato M, Chiew KH, Khan T, Kicinski M, Kohrer S, Kornblau SM, Kotecha RS, Li CK, Liu YC, Locatelli F, Luger SM, Paietta EM, Manabe A, Marquart HV, Masetti R, Maybury M, Mazilier P, Meijerink JPP, Mitchell S, Miyamura T, Moore AS, Oshima K, Pawinska-Wasikowska K, Pieters R, Prater MS, Pruett-Miller SM, Pui CH, Qu C, Reiterova M, Reyes N, Roberts KG, Rowe JM, Sato A, Schmiegelow K, Schrappe M, Shen S, Skoczen S, Spinelli O, Stary J, Svaton M, Takagi M, Takita J, Tang Y, Teachey DT, Thomas PG, Tomizawa D, Trka J, Varotto E, Vincent TL, Yang JJ, Yeoh AE, Zhou Y, Zimmermann M, Inaba H, Mullighan CG. Biologic and clinical analysis of childhood gamma delta T-ALL identifies LMO2/STAG2 rearrangements as extremely high-risk. Cancer Discov, 2024. e-Pub 2024. PMID: 38916500.
21. Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Monovich AC, Narina S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Pruett-Miller SM, Ryan RJH, Yang JJ, Evans WE, Savic D. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genom 3(12), 2023. e-Pub 2023. PMID: 38116118.
22. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined Inhibition of BCL-2 and MCL-1 Overcomes BAX Deficiency-Mediated Resistance of TP53-mutant Acute Myeloid Leukemia to Individual BH3 Mimetics. Blood Cancer J 13(1), 2023. e-Pub 2023. PMID: 37088806.
23. Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1), 2023. e-Pub 2023. PMID: 37386016.
24. Kimura S, Polonen P, Montefiori L, Park CS, Iacobucci I, Yeoh AE, Attarbaschi A, Moore AS, Brown A, Manabe A, Buldini B, Freeman BB, Chen C, Cheng C, Kean Hui C, Li CK, Pui CH, Qu C, Tomizawa D, Teachey DT, Varotto E, Paietta EM, Arnold ED, Locatelli F, Escherich G, Elisa Muhle H, Marquart HV, de Groot-Kruseman HA, Rowe JM, Stary J, Trka J, Choi JK, Meijerink JPP, Yang JJ, Takita J, Pawinska-Wasikowska K, Roberts KG, Han K, Caldwell KJ, Schmiegelow K, Crews KR, Eguchi M, Schrappe M, Zimmerman M, Takagi M, Maybury M, Svaton M, Reiterova M, Kicinski M, Prater MS, Kato M, Reyes N, Spinelli O, Thomas P, Mazilier P, Gao Q, Masetti R, Kotecha RS, Pieters R, Elitzur S, Luger SM, Mitchell S, Pruett-Miller SM, Shen S, Jeha S, Köhrer S, Kornblau SM, Skoczen S, Miyamura T, Vincent TL, Imamura T, Conter V, Tang Y, Liu YC, Chang Y, Gu Z, Cheng Z, Yinmei Z, Inaba H, Mullighan CG. Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 γδ T-ALL as an extremely high risk leukemia in the very young. medRxiv, 2023. e-Pub 2023. PMID: 37986997.
25. Hoff FW, Qiu Y, Brown BD, Gerbing RB, Leonti AR, Ries RE, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, Horton TM, Kornblau SM. Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl 17(6), 2023. e-Pub 2023. PMID: 37287368.
26. Rowland L, Smart B, Brown A, Dettorre GM, Gocho Y, Hunt J, Yang W, Yoshimura S, Reyes N, Du G, John A, Maxwell D, Stock W, Kornblau S, Relling MV, Inaba H, Pui CH, Bourquin JP, Karol SE, Mullighan CG, Evans WE, Yang JJ, Crews KR. Ex Vivo Drug Sensitivity Imaging-Based Platform for Primary Acute Lymphoblastic Leukemia Cells. Bio Protoc 13(15), 2023. e-Pub 2023. PMID: 37575398.
27. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultra-sensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR:ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
28. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1), 2023. e-Pub 2023. PMID: 37193700.
29. Wright S, Hu J, Wang H, Hyle J, Zhang Y, Du G, Konopleva MY, Kornblau SM, Djekidel MN, Rosikiewicz W, Xu B, Lu R, Yang JJ, Li C. Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proc Natl Acad Sci U S A 120(16), 2023. e-Pub 2023. PMID: 37036970.
30. Ramabadran R, Wang JH, Reyes JM, Guzman AG, Gupta S, Rosas C, Brunetti L, Gundry MC, Tovy A, Long H, Gu T, Cullen SM, Tyagi S, Rux D, Kim JJ, Kornblau SM, Kyba M, Stossi F, Rau RE, Takahashi K, Westbrook TF, Goodell MA. DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. Nat Cell Biol 25(4):528-539, 2023. e-Pub 2023. PMID: 37024683.
31. Hoff FW, Griffen TL, Brown BD, Horton TM, Burger J, Wierda W, Hubner SE, Qiu Y, Kornblau SM. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci 24(6), 2023. e-Pub 2023. PMID: 36982537.
32. Griffen TL, Hoff FW, Qiu Y, Burger J, Wierda W, Kornblau SM. Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia. Int J Mol Sci 24(6), 2023. e-Pub 2023. PMID: 36982555.
33. Hubner SE, de Camargo Magalhães ES, Hoff FW, Brown BD, Qiu Y, Horton TM, Kornblau SM. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study. Int J Mol Sci 24(6), 2023. e-Pub 2023. PMID: 36982970.
34. Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq, 2023. e-Pub 2023. PMID: 36865338.
35. Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Yang JJ, Evans WE, Savic D. Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures. bioRxiv, 2023. e-Pub 2023. PMID: 36824825.
36. Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. medRxiv, 2023. e-Pub 2023. PMID: 36798219.
37. Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-cell malignancies. Clin Cancer Res 29(2):446-457, 2023. e-Pub 2023. PMID: 36346691.
38. Aitken MJL, Malaney P, Zhang X, Herbrich SM, Chan L, Benitez O, Rodriguez AG, Ma H, Jacamo R, Duan R, Link TM, Kornblau SM, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. NAR Cancer 4(4):zcac039, 2022. e-Pub 2022. PMID: 36518526.
39. Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun 13(1):2801, 2022. e-Pub 2022. PMID: 35589701.
40. Hoff FW, Griffen TL, Qiu Y, Kornblau SM. Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL-variant. EJHaem 3(4):1321-1325, 2022. e-Pub 2022. PMID: 36467805.
41. Abuasab T, Alvarado Y, Issa G, Islam R, James N, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Pemmaraju N, Bravo GM, Pierce S, DiNardo C, Kadia T, Daver N, Konopleva M, Garcia-Manero G, Ravandi F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clin Lymphoma Myeloma Leuk 22:S237, 2022. e-Pub 2022. PMID: 36163813.
42. Hoff FW, Van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Qutub AA, ESJM DB, Horton TM, Kornblau SM. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica 107(10):2329-2343, 2022. e-Pub 2022. PMID: 35021602.
43. Hoff FW, van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Neshinchi S, Qutub AA, ESJM DB, Horton TM, Kornblau SM. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group Study. Haematologica 107:23292343, 2022. e-Pub 2022. PMID: 35021602.
44. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A Randomized Phase III Study of Pretransplant Conditioning for AML/MDS with Fludarabine and Once Daily IV Busulfan ± Clofarabine in Allogeneic Stem Cell Transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
45. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
46. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
47. Thomas GE, Egan G, García-Prat L, Botham A, Voisin V, Patel PS, Hoff FW, Chin J, Nachmias B, Kaufmann KB, Khan DH, Hurren R, Wang X, Gronda M, MacLean N, O'Brien C, Singh RP, Jones CL, Harding SM, Raught B, Arruda A, Minden MD, Bader GD, Hakem R, Kornblau S, Dick JE, Schimmer AD. The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. Nat Cell Biol 24(6):872-884, 2022. e-Pub 2022. PMID: 35668135.
48. El Hussein S, Daver N, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk 22(6):e386-e391, 2022. e-Pub 2022. PMID: 34980577.
49. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, ESJM DB, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia 36(3):712-722, 2022. e-Pub 2022. PMID: 34625713.
50. van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins G, ESJM DB, Kornblau SM, Horton TM. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA. Proteomics Clin Appl 16(2), 2022. e-Pub 2022. PMID: 34719869.
51. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J 12(3):43, 2022. e-Pub 2022. PMID: 35301276.
52. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2022. PMID: 34601571.
53. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):672-675, 2022. e-Pub 2022. PMID: 34668451.
54. Youn M, Smith SM, Lee AG, Chae HD, Spiteri E, Erdmann J, Galperin I, Jones LM, Donato M, Abidi P, Bittencourt H, Lacayo N, Dahl G, Aftandilian C, Davis KL, Matthews JA, Kornblau SM, Huang M, Sumarsono N, Redell MS, Fu CH, Chen IM, Alonzo TA, Eklund E, Gotlib J, Khatri P, Sweet-Cordero EA, Hijiya N, Sakamoto KM. Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers (Basel) 6263(24), 2021. e-Pub 2021. PMID: 34944883.
55. Hoff FW, Horton TM, Kornblau SM. Reverse Phase Protein Arrays in Acute Leukemia: Investigative and Methodological Challenges. Expert Rev Proteomics 18(12):1-11, 2021. e-Pub 2021. PMID: 34965151.
56. Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy. Blood Adv 5(22):4569-4574, 2021. e-Pub 2021. PMID: 34555853.
57. Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. e-Pub 2021. PMID: 34732043.
58. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 Mutations Over the Course of Therapy for Acute Myeloid Leukemia. Am J Hematol 96(11):1420-1428, 2021. e-Pub 2021. PMID: 34351647.
59. Montefiori LE, Bendig S, Gu Z, Chen X, Pölönen P, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, Litzow MR, Rowe JM, den Boer ML, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CG. Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. Cancer Discov 11(11):2846-2867, 2021. e-Pub 2021. PMID: 34103329.
60. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell Landscape and T Cell Receptor Repertoire Profiling of AML in Context of PD-1 Blockade Therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
61. Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
62. Heltemes-Harris LM, Hubbard GK, LaRue RS, Munro SA, Yang R, Henzler CM, Starr TK, Sarver AL, Kornblau SM, Farrar MA. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia. Oncogene 40(43):6166-6179, 2021. e-Pub 2021. PMID: 34535769.
63. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
64. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
65. Butler M, van Ingen Schenau DS, Yu J, Jenni S, Dobay MP, Hagelaar R, Vervoort BMT, Tee TM, Hoff FW, Meijerink JP, Kornblau SM, Bornhauser B, Bourquin JP, Kuiper RP, van der Meer LT, van Leeuwen FN. BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway. Blood. e-Pub 2021. PMID: 34280258.
66. Griffen TL, Dammer EB, Dill CD, Carey KM, Young CD, Nunez SK, Ohandjo AQ, Kornblau SM, Lillard JW. Multivariate Transcriptome Analysis Identifies Networks and Key Drivers of Chronic Lymphocytic Leukemia Relapse Risk and Patient Survival. BMC Med Genomics 14(1):171, 2021. e-Pub 2021. PMID: 34187466.
67. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
68. Kaeding AJ, Barwe SP, Gopalakrishnapillai A, Ries RE, Alonzo TA, Gerbing RB, Correnti C, Loken MR, Broderson LE, Pardo L, Le QH, Tang T, Leonti AR, Smith JL, Chou CK, Xu M, Triche T, Kornblau SM, Kolb EA, Tarlock K, Meshinchi S. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Adv 5(9):2350-2361, 2021. e-Pub 2021. PMID: 33938941.
69. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
70. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia After Frontline Hypomethylating Agent and Venetoclax Regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
71. Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Rowland L, Shi L, Maxwell D, Smart B, Crews K, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer 2(3):284-299, 2021. e-Pub 2021. PMID: 34151288.
72. Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, ESJM DB, Bruggeman SWM, Kornblau SM, Horton TM. Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study. Blood 137(8):1050-1060, 2021. e-Pub 2021. PMID: 32959058.
73. van Dijk AD, Hoff FW, Qiu YH, Chandra J, Jabbour E, ESJM DB, Horton TM, Kornblau SM. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clin Epigenetics 13(1):21, 2021. e-Pub 2021. PMID: 33509276.
74. Farrar W, Kornblau SM. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia. Leukemia, 2021.
75. Abbas HA, Mohanty V, Wang R, Huang Y, Liang S, Wang F, Zhang J, Qiu Y, Hu CW, Qutub AA, Dail M, Bolen CR, Daver N, Konopleva M, Futreal A, Chen K, Wang L, Kornblau SM. Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Front Oncol 11:705627, 2021. e-Pub 2021. PMID: 34422660.
76. Yang X, Kornblau SM. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature, 2021. PMID: 34151288.
77. Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, Qiu Y, Wang T, Mo Q, Kornblau SM. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): functional proteomic profiling in leukemia. J Proteomics:104046, 2021. e-Pub 2020. PMID: 33212251.
78. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II Trial of CPX-351 in Patients with Acute Myeloid Leukemia at High Risk for Induction Mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
79. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
80. Chae HD, Dutta R, Tiu B, Hoff FW, Accordi B, Serafin V, Youn M, Huang M, Sumarsono N, Davis KL, Lacayo NJ, Pigazzi M, Horton TM, Kornblau SM, Sakamoto KM. RSK inhibitor BI-D1870 Inhibits Acute Myeloid Leukemia Cell Proliferation by Targeting Mitotic Exit. Oncotarget 11(25):2387-2403, 2020. e-Pub 2020. PMID: 32637030.
81. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J 10(5):61, 2020. e-Pub 2020. PMID: 32457305.
82. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
83. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical Value of Event-Free Survival in Acute Myeloid Leukemia. Blood Adv 4(8):1690-1699, 2020. e-Pub 2020. PMID: 32330243.
84. Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, Jitkova Y, Nachmias B, MacLean N, Wang X, Arruda A, Minden MD, Horton TM, Kornblau SM, Chan SM, Bader GD, Raught B, Schimmer AD. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci Transl Med 12(538), 2020. e-Pub 2020. PMID: 32269163.
85. Ohanian M, Telouk P, Kornblau S, Albarede F, Ruvolo P, Tidwell RSS, Plesa A, Kanagal-Shamanna R, Matera EL, Cortes J, Carson A, Dumontet C. A heavy metal baseline score predicts outcome in AML. Am J Hematol 95(4):422-434, 2020. e-Pub 2020. PMID: 31944361.
86. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791-803, 2020. e-Pub 2020. PMID: 31932844.
87. Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer 1(3):329-344, 2020. e-Pub 2020. PMID: 32885175.
88. van Dijk AD, ESJM DB, Kornblau SM. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. Expert Rev Proteomics 17(1):1-10, 2020. e-Pub 2020. PMID: 31945303.
89. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma:1-8, 2020. e-Pub 2020. PMID: 32755333.
90. Ohanian M, Kantarjian HM, Kornblau SM. The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia. American Journal of Hematology, 2020. PMID: 32557828.
91. Konopleva M, DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger J, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch J, Kantarjian HM. Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia. The Lancet, 2020.
92. Kornblau SM. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Nature, 2020. PMID: 32099037.
93. Hu CW, Qiu Y, Ligeralde A, Raybon AY, Yoo SY, Coombes KR, Qutub AA, Kornblau SM. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia. Nat Biomed Eng 3(11):889-901, 2019. e-Pub 2019. PMID: 30988472.
94. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
95. Alfayez M, Wang SA, Bannon SA, Kontoyiannis DP, Kornblau SM, Orange JS, Mace EM, DiNardo CD. Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype. Leuk Lymphoma 60(8):1-9, 2019. e-Pub 2019. PMID: 30648453.
96. Mahmud H, Ter Elst A, Scherpen FJG, Boer TM, Kampen KR, de Haas V, Guryev V, Peppelenbosch MM, Kornblau SM, ESJM DB. Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair. Oncotarget 10(45):4679-4690, 2019. e-Pub 2019. PMID: 31384395.
97. Griffen T, Kornblau SM. Proteomics Exploration of Chronic Lymphocytic Leukemia. Novel Approaches in Cancer Study 30(1):1-3, 2019. e-Pub 2019.
98. Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, Abbas HA, Post SM, ESJM DB, Kornblau SM. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics Clin Appl 13(4):e1800133, 2019. e-Pub 2019. PMID: 30650251.
99. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 134(1):59-73, 2019. e-Pub 2019. PMID: 31023702.
100. Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine 44:126-137, 2019. e-Pub 2019. PMID: 31105032.
101. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 2019. e-Pub 2019. PMID: 30500073.
102. De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP. Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease. Bone Marrow Transplant 54(5):749-751, 2019. e-Pub 2019. PMID: 30323308.
103. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2019. PMID: 30409776.
104. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 51(2):296-307, 2019. e-Pub 2019. PMID: 30643249.
105. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of co-treatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
106. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
107. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC Protein Expression is an Important Prognostic Factor in Acute Myeloid Leukemia. Leuk Lymphoma 60(1):1-12, 2019. e-Pub 2019. PMID: 29741984.
108. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
109. Ravandi F, Assi R, Daver N, Benton C, Kadia T, Thompson P, Borthakur B, Alvarado Y, Jabbour E, Konopleva M, Takahashi K, Kornblau SM, DiNardo C, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes J, Garcia-Manero G, Kantarjian H. Phase II Trial of Idarubicin, Cytarabine and Nivolumab in Patients with Newly Diagnosed Acute Myeloid Leukaemia and High-Risk Myelodysplastic Syndrome. The Lancet Oncology, 2019. PMID: 31400961.
110. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival. Am J Hematol 93(11):1376-1383, 2018. e-Pub 2018. PMID: 30117185.
111. Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, HJMP V, De Keersmaecker K, Smit L, Kornblau SM, ESJM DB. VEGFC antibody therapy drives differentiation of AML. Cancer Res 78(20):5940-5948, 2018. e-Pub 2018. PMID: 30185550.
112. Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 18(10):658-663.e2, 2018. e-Pub 2018. PMID: 30001986.
113. Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell 34(3):499-512.e9, 2018. e-Pub 2018. PMID: 30205049.
114. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Scheurer ME, ESJM DB, Qutub AA, Kornblau SM, Horton TM. Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Mol Cancer Res 16(8):1263-1274, 2018. e-Pub 2018. PMID: 29669823.
115. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, ESJM DB, Qutub AA, Horton TM, Kornblau SM. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res 16(8):1275-1286, 2018. e-Pub 2018. PMID: 29669821.
116. Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC derived Galectin 3 in the AML microenvironment. Biochim Biophys Acta Volume 1865(Issue 7):959-969, 2018. e-Pub 2018. PMID: 29655803.
117. Hoff FW, Hu CW, Qutub AA, ESJM DB, Horton TM, Kornblau SM. Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Rev Proteomics 15(7):613-622, 2018. e-Pub 2018. PMID: 29898608.
118. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
119. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59(6):1-11, 2018. e-Pub 2018. PMID: 28972430.
120. Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Disruption of Wnt/β-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia. Clin Cancer Res 24(10):2417-2429, 2018. e-Pub 2018. PMID: 29463558.
121. Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N, Konopleva M, Andreeff M. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103(5):810-821, 2018. e-Pub 2018. PMID: 29545342.
122. Kornblau SM, Ruvolo PP, R-Y W, Battula VL, Shpall EJ, Ruvolo V, McQueen T, Qiu Y, Zeng Z, Pierce S, Jacamo R, S-Y Y, Le P, Sun J, Hail N, Konopleva, Andreeff M. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103, 2018. PMID: 29545342.
123. van Dijk AD, Hu CW, ESJM DB, Qiu Y, Hoff FW, Yoo SY, Coombes KR, Qutub AA, Kornblau SM. Histone Modification Patterns using RPPA-based Profiling Predict Outcome in Acute Myeloid Leukemia Patients. Proteomics 18(8):e1700379, 2018. e-Pub 2018. PMID: 29505696.
124. Li T, Liu Q, Garza N, Kornblau S, Jin VX. Integrative analysis reveals functional and regulatory roles of H3K79me2 in mediating alternative splicing. Genome Med 10(1):30, 2018. e-Pub 2018. PMID: 29665865.
125. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
126. Boddu P, Chen PL, Nagarajan P, Prieto VG, Won A, Chambers M, Kornblau S. Necrotizing fungal gingivitis in a patient with Acute Myelogenous Leukemia: visible yet obscure. J Oral Maxillofac Surg Med Pathol 30(1):50-54, 2018. e-Pub 2018. PMID: 29404266.
127. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
128. Wang M, Abrams ZB, Kornblau SM, Coombes KR. Thresher: Determining the Number of Clusters while Removing Outliers. BMC Bioinformatics 19(9):1-15, 2018. e-Pub 2018. PMID: 29310570.
129. Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R. Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9(4):4354-4365, 2018. e-Pub 2018. PMID: 29435107.
130. Wang M, Kornblau SM, Coombes KR. Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components. Cancer Inform 17:1176935118771082, 2018. e-Pub 2018. PMID: 29881252.
131. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting Nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia, 2018. e-Pub 2018. PMID: 30575820.
132. Hoff FW, Hu CW, Qutub AA, Qiu Y, Graver E, Hoang G, Chauhan M, ESJM DB, Kornblau SM. Mycoplasma Contamination of Leukemic Cell Lines Alters Protein Expression Determined by Reverse Phase Protein Arrays. Cytotechnology, 2018. e-Pub 2018. PMID: 30191439.
133. Post SM, Kornblau SM, Quintás-Cardama A. p53 pathway dysfunction in AML: beyond TP53 mutations. Oncotarget 8(65):108288-108289, 2017. e-Pub 2017. PMID: 29312530.
134. Ding L, Sun QY, Tan KT, Chien W, Thippeswamy AM, Eng Juh AY, Kawamata N, Nagata Y, Xiao JF, Loh XY, Lin DC, Garg M, Lim SL, Liu LZ, Madan V, Jiang YY, Xu L, Sanada M, Fernández LT, Preethi H, Lill M, Kantarjian H, Kornblau SM, Miyano S, Ogawa S, Liang DC, Shih LY, Yang H, Koeffler HP. Mutational landscape of pediatric acute lymphoblastic leukemia. Cancer Res, 2017. e-Pub 2016. PMID: 27872090.
135. Kelly AD, Kroeger H, Yamazaki J, Taby R, Neumann F, Yu S, Lee JT, Patel B, Li Y, He R, Liang S, Lu Y, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Jelinek J, Issa JP. A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. Leukemia 31(10):2011-2019, 2017. e-Pub 2017. PMID: 28074068.
136. Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M. Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8(48):83354-83369, 2017. e-Pub 2017. PMID: 29137349.
137. Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102(9):1537-1548, 2017. e-Pub 2017. PMID: 28659338.
138. Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv 1(19):1546-1550, 2017. e-Pub 2017. PMID: 29296796.
139. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci 18(8), 2017. e-Pub 2017. PMID: 28933735.
140. Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, Kornblau SM, Farrar MA. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol 18(6):694-704, 2017. e-Pub 2017. PMID: 28369050.
141. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
142. Quintás-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, Zhang N, Coombes K, Kornblau SM. P53 Pathway Dysfunction Is Highly Prevalent in Acute Myeloid Leukemia Independent of Tp53 Mutational Status. Leukemia 31(6):1296-1305, 2017. e-Pub 2017. PMID: 27885271.
143. Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16(6):1133-1144, 2017. e-Pub 2017. PMID: 28270436.
144. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
145. Butler JS, Qiu YH, Zhang N, Yoo SY, Coombes KR, Dent SY, Kornblau SM. Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia. Leuk Lymphoma 58(5):1207-1218, 2017. e-Pub 2017. PMID: 28185526.
146. Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B cell acute leukemia. Blood 129(14):1958-1968, 2017. e-Pub 2017. PMID: 28143883.
147. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2017. PMID: 28003274.
148. Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature 542(7642):1-5, 2017. e-Pub 2017. PMID: 28192788.
149. Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a Clinical Assay of Multi-Locus DNA Methylation for Prognosis of Newly Diagnosed AML. Am J Hematol 92(2):E14-E15, 2017. e-Pub 2017. PMID: 27804182.
150. Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35(4):JCO2016690073, 2017. e-Pub 2017. PMID: 27870571.
151. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood 129(5):572-581, 2017. e-Pub 2017. PMID: 27919910.
152. Liu L, Chang Y, Yang T, Noren DP, Long B, Kornblau S, Qutub A, Ye J. Evolution-informed modeling improves outcome prediction for cancers. Evol Appl 10(1):68-76, 2017. e-Pub 2017. PMID: 28035236.
153. Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T, Garg M, Lim SL, Madan V, Hattori N, Nagata Y, Miyano S, Yeoh AE, Hou HA, Jiang YY, Takao S, Liu LZ, Tan SZ, Lill M, Hayashi M, Kinoshita A, Kantarjian HM, Kornblau SM, Ogawa S, Haferlach T, Yang H, Koeffler HP. Ordering of Mutations in Acute Myeloid Leukemia with Partial Tandem Duplication of MLL (MLL-PTD). Leukemia 31(1):1-10, 2017. e-Pub 2017. PMID: 27389053.
154. Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31(1):234-237, 2017. e-Pub 2017. PMID: 27573556.
155. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2017. PMID: 27673440.
156. Brown FC, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp KM, Alonzo TA, Meshinchi S, Stone RM, Kornblau SM, Marcucci G, Gamis AS, Byrd JC, Gonen M, Levine RL, Kentsis A. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol 176(1):86-91, 2017. e-Pub 2017. PMID: 27766616.
157. Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors. Nature, 2017. e-Pub 2018. PMID: 29849140.
158. Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol 8:1975, 2017. e-Pub 2017. PMID: 29422892.
159. Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrózek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG, Genome Project SJCRHUPC. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 48(12):1481-1489, 2016. e-Pub 2016. PMID: 27776115.
160. Kornblau SM. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Genetics, 2016. PMID: 27824051.
161. Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 7:13331, 2016. e-Pub 2016. PMID: 27824051.
162. Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M, Ogretmen B. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood 128(15):1944-1958, 2016. e-Pub 2016. PMID: 27540013.
163. Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood 128(9):1260-9, 2016. e-Pub 2016. PMID: 27268264.
164. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia 30(12):1672-81, 2016. e-Pub 2016. PMID: 27063598.
165. Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. Oncotarget 7(34):55083-55097, 2016. e-Pub 2016. PMID: 27391151.
166. Mahmud H, Kornblau SM, Ter Elst A, Scherpen FJ, Qiu YH, Coombes KR, de Bont ES. Epidermal Growth Factor Receptor is expressed and active in a subset of Acute Myeloid Leukemia. J Hematol Oncol 9(1):64, 2016. e-Pub 2016. PMID: 27488458.
167. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-münster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819-23, 2016. e-Pub 2016. PMID: 27178680.
168. Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE. Mixed Phenotype Acute Leukemia (MPAL) Exhibits Frequent Mutations in DNMT3A and Activated Signaling Genes. Exp Hematol 44(8):740-4, 2016. e-Pub 2016. PMID: 27208809.
169. Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, Campbell CT, Daigle SR, Deng L, Song Y, Sweet S, Chevassut T, Andreeff M, Kornblau SM, Li W, Goodell MA. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128(7):971-81, 2016. e-Pub 2016. PMID: 27335278.
170. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk 16(7):417-428.e2, 2016. e-Pub 2016. PMID: 27210295.
171. Noren DP, Long BL, Norel R, Rrhissorrakrai K, Hess K, Hu CW, Bisberg AJ, Schultz A, Engquist E, Liu L, Lin X, Chen GM, Xie H, Hunter GA, Boutros PC, Stepanov O, Consortium DA, Norman T, Friend SH, Stolovitzky G, Kornblau S, Qutub AA. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Comput Biol 12(6):e1004890, 2016. e-Pub 2016. PMID: 27351836.
172. Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget 7(15):20054-67, 2016. e-Pub 2016. PMID: 26956049.
173. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekoffer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LaBoeuf N, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 29(4):574-86, 2016. e-Pub 2016.
174. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med 22(4):379-87, 2016. e-Pub 2016. PMID: 26974310.
175. Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IL, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z, Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 29(2):186-200, 2016. e-Pub 2016. PMID: 26859458.
176. Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP. Hypomethylation of TET2 target genes identifies a curable subset of acute myeloid leukemia. J Natl Cancer Inst 108(2), 2016. e-Pub 2016. PMID: 26568194.
177. Schultz A, Mehta S, Hu CW, Hoff FW, Horton TM, Kornblau SM, Qutub AA. Identifying Cancer Specific Metabolic Signatures using Constraint-based Models. Pac Symp Biocomput 22:485-496, 2016. e-Pub 2016. PMID: 27897000.
178. Nishida Y, Maeda A, Chachad D, Ishizawa J, Qiu YH, Kornblau SM, Kimura S, Andreeff M, Kojima K. Preclinical activity of the novel BMI-1 inhibitor PTC-209 in acute myeloid leukemia: implications for leukemia therapy. Cancer Sci 106(12):1705-13, 2015. e-Pub 2015. PMID: 26450753.
179. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep 13(12):2715-27, 2015. e-Pub 2015. PMID: 26711339.
180. Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation of GSK3 α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clin 4:59-68, 2015. e-Pub 2015. PMID: 26674329.
181. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP. Profiling of somatic mutations of acute myeloid leukemia, FLT3-ITD subgroup at diagnosis and relapse. Blood 126(22):2491-501, 2015. e-Pub 2015. PMID: 26438511.
182. Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell 28(4):486-99, 2015. e-Pub 2015. PMID: 26412324.
183. Cheng X, Byrne M, Brown KD, Konopleva MY, Kornblau SM, Bennett RL, May WS. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood 126(13):1585-94, 2015. e-Pub 2015. PMID: 26202421.
184. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. e-Pub 2015. PMID: 26436130.
185. Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell 28(1):114-28, 2015. e-Pub 2015. PMID: 26073130.
186. Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal Evolution of Acute Myeloid Leukemia Relapsed after 19 Years of Remission. Am J Hematol 90(7):E134-5, 2015. e-Pub 2015. PMID: 25801490.
187. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
188. Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, Al-Awar R, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell 27(6):864-876, 2015. e-Pub 2015. PMID: 26058080.
189. van der Sligte NE, Kampen KR, ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Guryev V, van Leeuwen FN, Kornblau SM, de Bont ES. Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia. Oncotarget 6(17):14970-81, 2015. e-Pub 2015. PMID: 26008971.
190. Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES. EphB1 Suppression in Acute Myeloid Leukemia: Regulating the DNA Damage Control System. Mol Cancer Res 13(6):982-92, 2015. e-Pub 2015. PMID: 25944917.
191. McGee SF, Kornblau SM, Qiu Y, Look AT, Zhang N, Yoo SY, Coombes KR, Kentsis A. Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia. Leukemia 29(5):1218-21, 2015. e-Pub 2015. PMID: 25541150.
192. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A 87(4):346-56, 2015. e-Pub 2015. PMID: 25598437.
193. Hamdi A, Cao K, Poon LM, Aung F, Kornblau S, Fernandez Vina MA, Champlin RE, Ciurea SO. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?. Bone Marrow Transplant 50(3):411-3, 2015. e-Pub 2015. PMID: 25621795.
194. Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell 27(3):409-25, 2015. e-Pub 2015. PMID: 25759025.
195. Quintás-Cardama A, Zhang N, Qiu YH, Post S, Creighton CJ, Cortes J, Coombes KR, Kornblau SM. Loss of TRIM62 Expression Is an Independent Adverse Prognostic Factor in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):115-127.e15, 2015. e-Pub 2015. PMID: 25248926.
196. Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 125(4):680-6, 2015. e-Pub 2015. PMID: 25468567.
197. Hu CW, Kornblau SM, Slater JH, Qutub AA. Progeny Clustering: a Method to Identify Biological Phenotypes. Sci Rep 5:12894, 2015. e-Pub 2015. PMID: 26267476.
198. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120(23):3660-8, 2014. e-Pub 2014. PMID: 25042398.
199. Oancea C, Rüster B, Brill B, Roos J, Heinssmann M, Bug G, Mian AA, Guillen NA, Kornblau SM, Henschler R, Ruthardt M. STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes Cancer 5(11-12):378-92, 2014. e-Pub 2014. PMID: 25568664.
200. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol 167(3):376-84, 2014. e-Pub 2014. PMID: 25079338.
201. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable kinase activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371(11):1005-1015, 2014. e-Pub 2014. PMID: 25207766.
202. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell 26(3):428-42, 2014. e-Pub 2014. PMID: 25132497.
203. Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N, Konopleva M, Calin G, Kornblau SM, Andreeff M. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta 1843(9):1969-77, 2014. e-Pub 2014. PMID: 24858343.
204. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28(8):1657-65, 2014. e-Pub 2014. PMID: 24451410.
205. Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Proia D, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S. WTAP is a Novel Oncogenic Protein in Acute Myeloid Leukemia. Leukemia 28(5):1171-4, 2014. e-Pub 2014. PMID: 24413322.
206. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res 20(8):2226-35, 2014. e-Pub 2014. PMID: 24583795.
207. Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R. Implications of the miR-10 family in chemotherapy response of NPM1 mutated AML. Blood 123(15):2412-5, 2014. e-Pub 2014. PMID: 24596420.
208. Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis 19(4):698-707, 2014. e-Pub 2014. PMID: 24337870.
209. Karjalainen K, Pasqualini R, Cortes JE, Kornblau SM, Lichtiger B, O'Brien S, Kantarjian HM, Sidman RL, Arap W, Koivunen E. Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia. Cancer 120(4):589-602, 2014. e-Pub 2014. PMID: 24496871.
210. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. J Natl Cancer Inst 106(2):djt440, 2014. e-Pub 2014. PMID: 24526787.
211. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. BH3 Profiling Discriminates Response to Cytarabine-based Treatment of Acute Myeloid Leukemia. Mol Cancer Ther 12(12):2940-9, 2013. e-Pub 2013. PMID: 24092807.
212. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
213. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl) 22(5):605-11, 2013. e-Pub 2013. PMID: 23701251.
214. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 2013. e-Pub 2013. PMID: 23801633.
215. Kornblau SM, Cohen AC, Soper D, Huang YW, Cesano A. Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. Cytometry B Clin Cytom 86(6), 2013. e-Pub 2013. PMID: 24106013.
216. Pierce A, Whetton AD, Meyer S, Ravandi-Kashani F, Borthakur G, Coombes KR, Zhang N, Kornblau S. Transglutaminase2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility. Proteomics 13(14):2216-24, 2013. e-Pub 2013. PMID: 23576428.
217. Research Network CGA. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med DOI:10.1056(22):2059-74, 2013. e-Pub 2013. PMID: 23634996.
218. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121(20):4166-74, 2013. e-Pub 2013. PMID: 23564911.
219. Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, Melnick AM, Figueroa ME, Zweidler-McKay PA. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 210(2):321-37, 2013. e-Pub 2013. PMID: 23359069.
220. Yamazaki J, Estecio MR, Lu Y, Long H, Malouf GG, Graber D, Huo Y, Ramagli L, Liang S, Kornblau SM, Jelinek J, Issa JP. The epigenome of AML stem and progenitor cells. Epigenetics 8(1), 2013. e-Pub 2013. PMID: 23249680.
221. Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma 54(1):138-44, 2013. e-Pub 2013. PMID: 22691121.
222. Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra J. Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. PLoS One 8(8):e70608, 2013. e-Pub 2013. PMID: 23936456.
223. Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KR. Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells. PLoS One 8(10):e78453, 2013. e-Pub 2013. PMID: 24223100.
224. Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol 91(12):1861-70, 2012. e-Pub 2012. PMID: 22893484.
225. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR. An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell 22(5):683-697, 2012. e-Pub 2012. PMID: 23153540.
226. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 2012. e-Pub 2012. PMID: 22569880.
227. Quintás-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 118(21):5283-92, 2012. e-Pub 2012. PMID: 22517119.
228. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment. Blood 120(13):2679-89, 2012. e-Pub 2012. PMID: 22826565.
229. Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, Whichard Z, Chen Y, Kornblau S, Shpall EJ, Bueso-Ramos CE, Corey SJ. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene 31(37):4085-94, 2012. e-Pub 2012. PMID: 22249254.
230. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 13(10):858-70, 2012. e-Pub 2012. PMID: 22785211.
231. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 120(1):173-80, 2012. e-Pub 2012. PMID: 22645176.
232. York H, Kornblau SM, Qutub AA. Network Analysis of Reverse Phase Protein Expression Data: Characterizing Protein Signatures in Acute Myeloid Leukemia Cytogenetic Categories t(8;21) and inv(16). Proteomics 12(13):2084-93, 2012. e-Pub 2012. PMID: 22623292.
233. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic Significance of Alterations in IDH Enzyme Isoforms in Patients With AML Treated with High Dose Cytarabine and Idarubicin. Cancer 118(10):2665-73, 2012. e-Pub 2012. PMID: 22020636.
234. Ozpolat B, Akar U, Tekedereli I, Alpay SN, Barria M, Gezgen B, Zhang N, Coombes K, Kornblau S, Lopez-Berestein G. PKCδ Regulates Translation Initiation through PKR and eIF2α in Response to Retinoic Acid in Acute Myeloid Leukemia Cells. Leuk Res Treatment 2012:482905, 2012. e-Pub 2012. PMID: 23259068.
235. Neeley ES, Baggerly KA, Kornblau SM. Surface Adjustment of Reverse Phase Protein Arrays Using Positive Control Spots. Cancer Inform 2012(11):77-86, 2012. e-Pub 2012. PMID: 22550399.
236. Kornblau SM, Qiu YH, Zhang N, Singh N, Faderl S, Ferrajoli A, York H, Qutub AA, Coombes KR, Watson DK. Abnormal expression of friend leukemia virus integration 1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood 118(20):5604-12, 2011. e-Pub 2011. PMID: 21917756.
237. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia doi: 10. 1038(146):1711-7, 2011. e-Pub 2011. PMID: 21660042.
238. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia. Blood 118(13):3451-52, 2011. e-Pub 2011. PMID: 21725050.
239. Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, Thomas DA, Koeuth T, Baechler EC, Kornblau SM, Farrar MA. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med 208(6):1135-49, 2011. e-Pub 2011. PMID: 21606506.
240. Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M. Targeting PKC Mediated Signal Transduction Pathways Using Enzastaurin To Promote Apoptosis in Acute Myeloid Leukemia-Derived Cell Lines and Blast Cells. J Cell Biochem 112(6):1696-707, 2011. e-Pub 2011. PMID: 21360576.
241. Starkova J, Gadgil S, Qiu YH, Zhang N, Hermanova I, Kornblau SM, Drabkin HA. Upregulation of homeodomain genes, DLX1/2, by FLT3 signaling. Haematologica 96(6):820-8, 2011. e-Pub 2011. PMID: 21357706.
242. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a Role for Activation of Wnt/{beta}-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. J Biol Chem 286(13):11009-20, 2011. e-Pub 2011. PMID: 21189262.
243. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a Role for the Novel Zinc-finger Transcription Factor ZKSCAN3 in Modulating Cyclin D2 Expression in Multiple Myeloma. Oncogene 30(11):1329-40, 2011. e-Pub 2011. PMID: 21057542.
244. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-592, 2011. e-Pub 2011. PMID: 21241278.
245. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 117(3):780-787, 2011. e-Pub 2011. PMID: 21041716.
246. Telesca D, Muller P, Kornblau S, Suchard M, Ji Y. Modeling Protein Expression and Protein Signaling Pathways. Collection of Biostatistics Research Archive:87, 2011. e-Pub 2011.
247. Kornblau SM, Covey T, Putta S, Cohen A, Woronicz J, Fantl WJ, Gayko U, Cesano A. Signaling changes in the stem cell factor-AKT-S6 pathway in diagnostic AML samples are associated with disease relapse. Blood Cancer Journal 1(e3 doi:10.1038/bcj.2010.2), 2011. e-Pub 2011. PMID: 22829109.
248. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent Expression Signatures of Cytokines and Chemokines are Present and are Independently Prognostic in Acute Myelogenous Leukemia and Myelodysplasia. Blood 116(20):4251-61, 2010. e-Pub 2010. PMID: 20679526.
249. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. e-Pub 2010. PMID: 20805315.
250. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res 16(14):3721-33, 2010. e-Pub 2010. PMID: 20525753.
251. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 70(12):4949-60, 2010. e-Pub 2010. PMID: 20501850.
252. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia. Clin Cancer Res 16(6):1865-74, 2010. e-Pub 2010. PMID: 20215543.
253. Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 16(4):1149-58, 2010. e-Pub 2010. PMID: 20145167.
254. Kornblau SM, Minden MD, Hogge D, Cohen A, Cesano A. Insights into acute myeloid leukemia via single cell network profiling. Clin Lab Int 34(1):12-15, 2010. e-Pub 2010. PMID: 26726291.
255. Levin VA, Panchabhai SC, Shen L, Kornblau SM, Qiu Y, Baggerly KA. Different Changes in Protein and Phosphoprotein Levels Result from Serum Starvation of High-Grade Glioma and Adenocarcinoma Cell Lines. J Proteome Res 9(1):179-91, 2010. e-Pub 2010. PMID: 19894763.
256. Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, Cesano A. Functional Characterization of FLT3 Receptor Signaling Deregulation in Acute Myeloid Leukemia by Single Cell Network Profiling (SCNP). PLoS One 5(10):e13543, 2010. e-Pub 2010. PMID: 21048955.
257. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. MicroRNA 29b functions in acute myeloid leukemia. Blood 114(26):5331-41, 2009. e-Pub 2009. PMID: 19850741.
258. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23(9):1605-13, 2009. e-Pub 2009. PMID: 19387468.
259. Dotti G, Tian M, Savoldo B, Najjar A, Cooper LJ, Jackson J, Smith A, Mawlawi O, Uthamanthil R, Borne A, Brammer D, Paolillo V, Alauddin M, Gonzalez C, Steiner D, Decker WK, Marini F, Kornblau S, Bollard CM, Shpall EJ, Gelovani JG. Repetitive Noninvasive Monitoring of HSV1-tk-Expressing T Cells Intravenously Infused into Nonhuman Primates Using Positron Emission Tomography and Computed Tomography with 18F-FEAU. Mol Imaging 8(4):230-7, 2009. e-Pub 2009. PMID: 19728977.
260. Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. Variable Slope Normalization of Reverse Phase Protein Arrays. Bioinformatics 25(11):1384-9, 2009. e-Pub 2009. PMID: 19336447.
261. Poland KS, Shardy DL, Azim M, Naeem R, Krance RA, Dreyer ZE, Neeley ES, Zhang N, Qiu YH, Kornblau SM, Plon SE. Overexpression of ZNF342 by Juxtaposition with MPO Promoter/Enhancer in the Novel Translocation t(17;19)(q23;q13.32) in Pediatric Acute Myeloid Leukemia and Analysis of ZNF342 Expression in Leukemia. Genes Chromosomes Cancer 48(6):480-9, 2009. e-Pub 2009. PMID: 19255975.
262. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315-21, 2009. e-Pub 2009. PMID: 19369233.
263. Quintás-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115(11):2482-90, 2009. e-Pub 2009. PMID: 19280591.
264. Kornblau SM, Tibes R, Qiu Y, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional Proteomic Profiling of AML Predicts Response and Survival. Blood 113(1):154-164, 2009. e-Pub 2009. PMID: 18840713.
265. Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 32(11):1684-97, 2008. e-Pub 2008. PMID: 18339423.
266. Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Barón AE, Drabkin HA. HOX expression patterns identify a common signature for favorable AML. Leukemia 22(11):2041-2047, 2008. e-Pub 2008. PMID: 18668134.
267. Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22(5):965-70, 2008. e-Pub 2008. PMID: 18385750.
268. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6):3183-9, 2008. e-Pub 2008. PMID: 18187662.
269. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD. PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol 140(3):344-7, 2008. e-Pub 2008. PMID: 18053070.
270. Lennon PA, Abruzzo LV, Medeiros LJ, Cromwell C, Zhang X, Yin CC, Kornblau SM, Konopieva M, Lin P. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24). Cancer Genet Cytogenet 177(1):37-42, 2007. e-Pub 2007. PMID: 17693189.
271. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007. PMID: 17530009.
272. Sun K, Li M, Konopleva M, Konoplev S, Stephens LC, Kornblau SM, Frolova O, Wilkins DE, Ma W, Welniak LA, Andreeff M, Murphy WJ. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality. Biol Blood Marrow Transplant 13(5):521-9, 2007. e-Pub 2007. PMID: 17448911.
273. Kornblau SM, Aycox PG, Stephens C, McCue LD, Champlin RE, Marini FC. Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Exp Hematol 35(5):842-53, 2007. e-Pub 2007. PMID: 17577932.
274. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 109(7):2999-3006, 2007. e-Pub 2007. PMID: 17158228.
275. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109(7):1355-9, 2007. e-Pub 2007. PMID: 17326049.
276. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624-7, 2007. e-Pub 2007. PMID: 17223919.
277. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S, Berestein GL. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5(1):95-108, 2007. e-Pub 2007. PMID: 17259349.
278. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle 5(23):2769-77, 2006. e-Pub 2006. PMID: 17172852.
279. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5(10):2512-21, 2006. e-Pub 2006. PMID: 17041095.
280. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108(7):2358-65, 2006. e-Pub 2006. PMID: 16763210.
281. Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M, Ruvolo PP. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia 20(7):1316-9, 2006. e-Pub 2006. PMID: 16642043.
282. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58-60, 2006. e-Pub 2006. PMID: 16803568.
283. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66(7):3737-46, 2006. e-Pub 2006. PMID: 16585200.
284. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11(21):7817-24, 2005. e-Pub 2005. PMID: 16278404.
285. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615-24, 2005. e-Pub 2005. PMID: 16166440.
286. Kornblau SM, Womble M, Cade JS, Lemker E, Qiu YH. Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia 19(9):1550-7, 2005. e-Pub 2005. PMID: 15973452.
287. Heinrichs S, Berman JN, Ortiz TM, Kornblau SM, Neuberg DS, Estey EH, Look AT. CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome. Br J Haematol 130(1):83-6, 2005. e-Pub 2005. PMID: 15982348.
288. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29(6):649-52, 2005. e-Pub 2005. PMID: 15863204.
289. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3(10):1249-62, 2004. e-Pub 2004. PMID: 15486192.
290. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918-26, 2004. e-Pub 2004. PMID: 15254061.
291. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396-407, 2004. e-Pub 2004. PMID: 14551133.
292. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10(1 Pt 1):68-75, 2004. e-Pub 2004. PMID: 14734453.
293. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol 83 Suppl 1:S51-3, 2004. e-Pub 2004. PMID: 15124670.
294. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 102(12):4179-86, 2003. e-Pub 2003. PMID: 12920030.
295. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98(5):888-93, 2003. e-Pub 2003. PMID: 12942553.
296. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 98(1):81-5, 2003. e-Pub 2003. PMID: 12833459.
297. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97(9):2225-8, 2003. e-Pub 2003. PMID: 12712475.
298. Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, Dinauer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeek A, Apperley J, Ebeling S, Martens A, Kolb HJ, Weber M, Lotti F, Grande A, Weissinger E, Bueren JA, Lamana M, Falkenburg JH, Heemskerk MH, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, Introna M, Slavin S, Greenberg PD, Bregni M, Mavilio F, Bordignon C. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9(4):367-9, 2003. e-Pub 2003. PMID: 12669036.
299. Huaringa AJ, Kornblau SM, Tapia GG. Myelofibrosis with Myeloid Metaplasia and Antiphospholipid Syndrome: Coexistent Etiologies or Pulmonary Hypertension and Coagulation Factor II and V Deficiencies. Internet J Pulmonary Medicine 3:1-8. e-Pub 2003.
300. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8(7):2167-76, 2002. e-Pub 2002. PMID: 12114417.
301. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177-87, 2002. e-Pub 2002. PMID: 12114418.
302. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8(7):2217-24, 2002. e-Pub 2002. PMID: 12114423.
303. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99(9):3461-4, 2002. e-Pub 2002. PMID: 11964319.
304. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94(7):2024-32, 2002. e-Pub 2002. PMID: 11932905.
305. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 16(9):1888, 2002. e-Pub 2002. PMID: 12200720.
306. Albitar M, Manshouri T, Gidel C, Croce C, Kornblau S, Pierce S, Kantarjian HM. Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia. Leuk Res 25(10):859-64, 2001. e-Pub 2001. PMID: 11532518.
307. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108(6):851-9, 2001. e-Pub 2001. PMID: 11560954.
308. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92(2):406-13, 2001. e-Pub 2001. PMID: 11466696.
309. Kornblau SM, Stiouf I, Snell V, Przepiorka D, Stephens LC, Champlin R, Marini FC. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Res 61(8):3355-60, 2001. e-Pub 2001. PMID: 11309292.
310. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3):631-7, 2001. e-Pub 2001. PMID: 11157478.
311. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia 15(1):57-61, 2001. e-Pub 2001. PMID: 11243400.
312. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs 19(1):13-20, 2001. e-Pub 2001. PMID: 11291829.
313. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 89(9):1976-82, 2000. e-Pub 2000. PMID: 11064355.
314. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6(5):1796-803, 2000. e-Pub 2000. PMID: 10815900.
315. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 6(4):1401-9, 2000. e-Pub 2000. PMID: 10778970.
316. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res 5(12):4041-7, 1999. e-Pub 1999. PMID: 10632337.
317. Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk Lymphoma 35(5-6):483-9, 1999. e-Pub 1999. PMID: 10609785.
318. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13(11):1881-92, 1999. e-Pub 1999. PMID: 10557066.
319. Kornblau SM, Qiu YH. Altered expression of retinoblastoma (RB) protein in acute myelogenous leukemia does not result from methylation of the Rb promotor. Leuk Lymphoma 35(3-4):283-8, 1999. e-Pub 1999. PMID: 10706451.
320. Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17(9):2819-30, 1999. e-Pub 1999. PMID: 10561358.
321. Le XF, Groner Y, Kornblau SM, Gu Y, Hittelman WN, Levanon D, Mehta K, Arlinghaus RB, Chang KS. Regulation of AML2/CBFA3 in hematopoietic cells through the retinoic acid receptor alpha-dependent signaling pathway. J Biol Chem 274(31):21651-8, 1999. e-Pub 1999. PMID: 10419474.
322. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 5(7):1758-66, 1999. e-Pub 1999. PMID: 10430080.
323. Marini FC, Kornblau SM. Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition. Bone Marrow Transplant 23(9):907-15, 1999. e-Pub 1999. PMID: 10338046.
324. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 93(5):1668-76, 1999. e-Pub 1999. PMID: 10029596.
325. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 17(1):284-92, 1999. e-Pub 1999. PMID: 10458244.
326. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92(9):3090-7, 1998. e-Pub 1998. PMID: 9787143.
327. Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31(5-6):521-31, 1998. e-Pub 1998. PMID: 9922042.
328. Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res 4(8):1955-63, 1998. e-Pub 1998. PMID: 9717825.
329. Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM, Chang KS. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur J Haematol 60(4):217-25, 1998. e-Pub 1998. PMID: 9579874.
330. Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 16(3):882-9, 1998. e-Pub 1998. PMID: 9508169.
331. Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth AB. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med 4(3):158-64, 1998. e-Pub 1998. PMID: 9562974.
332. Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma 28(3-4):371-5, 1998. e-Pub 1998. PMID: 9517508.
333. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11(12):2039-44, 1997. e-Pub 1997. PMID: 9447817.
334. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 11(10):1661-4, 1997. e-Pub 1997. PMID: 9324286.
335. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11(10):1617-20, 1997. e-Pub 1997. PMID: 9324279.
336. Sacchi S, Kantarjian HM, O'Brien S, Beran M, Koller C, Pierce S, Kornblau S, Estey E, Keating MJ, Talpaz M. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia 11(10):1610-6, 1997. e-Pub 1997. PMID: 9324278.
337. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Kørbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531-6, 1997. e-Pub 1997. PMID: 9192777.
338. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15(5):1796-802, 1997. e-Pub 1997. PMID: 9164187.
339. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10(10):1563-9, 1996. e-Pub 1996. PMID: 8847890.
340. Claxton D, Xie QS, Patel S, Deisseroth AB, Kornblau S. The gene product of CBFB-MYH11. Leukemia 10(9):1479-85, 1996. e-Pub 1996. PMID: 8751466.
341. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma 21(1-2):85-92, 1996. e-Pub 1996. PMID: 8907274.
342. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13(11):2827-34, 1995. e-Pub 1995. PMID: 7595745.
343. Del Giglio A, Drach J, Kornblau SM, Patel S, Novaes M, Khetan R, Sawaya N, Dorlhiac-Llacer P, Chamone DF, Andreeff M. Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leuk Lymphoma 19(3-4):235-41, 1995. e-Pub 1995. PMID: 8535214.
344. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia 9(10):1735-41, 1995. e-Pub 1995. PMID: 7564518.
345. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1(9):1051-7, 1995. e-Pub 1995. PMID: 9816079.
346. Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1(1):21-8, 1995. e-Pub 1995. PMID: 9384660.
347. Zhang W, Xu HJ, Kornblau SM, Drach J, Hu SX, Andreeff M, Benedict WF, Deisseroth AB. Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. Leuk Lymphoma 16(3-4):191-8, 1995. e-Pub 1995. PMID: 7719226.
348. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau SM, Pike MC, Levine AM. Treatment of adult T-cell leukemia--lymphoma with a combination of interferon alfa and zidovudine. New England Journal of Medicine 332:1744-48, 1995. e-Pub 1995.
349. Kornblau SM, Xu HJ, Zhang W, Hu SX, Beran M, Smith TL, Hester J, Estey E, Benedict WF, Deisseroth AB. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood 84(1):256-61, 1994. e-Pub 1994. PMID: 8018920.
350. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12(4):671-8, 1994. e-Pub 1994. PMID: 7512125.
351. Kornblau SM, Chen N, del Giglio A, O'Brien S, Deisseroth AB. Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Res 54(1):242-6, 1994. e-Pub 1994. PMID: 8261446.
352. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 11 Suppl 2:59-63, 1993. e-Pub 1993. PMID: 7510196.
353. Deisseroth AB, Kantarjian HM, Talpaz M, Champlin RE, Reading CL, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X, Kornblau SM, Pollicardo N, Zhang W. Molecular approaches to the diagnosis and treatment of cancer. Stem Cell 11(Suppl 3):129-130, 1993. e-Pub 1993.
354. Deisseroth AB, Kavanagh JJ, Hanania EG, Fu S, Kornblau SM, Estey EH, Talpaz M, Kantarjian HM, Claxton DF, Reading CL, Dixon DA, Anderson RW, Lopez-Berstein G, Holmes FA, Logothetis CJ, Andreeff M, Benedict WF. Gene therapy: Chemoprotection, ummunoenhancement, and modification of tumor cells. The Cancer Bulletin 42(2):139-145, 1993. e-Pub 1993.
355. Kornblau SM, Xu HJ, del Giglio A, Hu SX, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res 52(17):4587-90, 1992. e-Pub 1992. PMID: 1511426.
356. Deisseroth AB, Zhang W, Cha Y, Yuan T, Chen H, Sims SH, Wedrychowski A, P-Q G, Huston LJ, Filaccio M, Claxton DF, Kornblau SM, Johnson EB, Howard OMZ, Andersson B, del Giglio A, Gressot L, Kantarjian HM, Talpaz M, Khouri I, Champlin RE, Andreeff M, Gaozza E, Seong DC, S-P S, Ellerson D, Hu G, Chou M. New directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma 6:89-95, 1992. e-Pub 1992.
357. Deisseroth AB, Herst CV, Wedrychowski A, Sims S, Seong D, Johnson E, Yuan T, Romine M, Paslidis N, Emerson S, Feinberg A, Gao P, Huston L, Claxton DF, Kornblau SM, LeMaistre F, Kantarjian HM, Talpaz M, Reading C, Spitzer G. Novel approaches to the therapy of cml. New Strategies in Bone Marrow Transplantation:163-169, 1991. e-Pub 1991.
358. Deisseroth AB, Herst CV, Wedrychowski A, Sims SH, Seong DC, Johnson EB, Yuan T, Romine ME, Paslidis N, P-Q G, Huston LJ, Claxton DF, Kornblau SM, Kantarjian HM, Talpaz M, Reading CL. Future directions in molecular and genetic therapy of leukemias and solid tumors. The Cancer Bulletin 42(3):173-180, 1990. e-Pub 1990.
359. Mazzone RW, Kornblau SM. Influence of vascular and transpulmonary pressures on endothelial vesicles in nonedematous and edematous lungs. Microvasc Res 25(3):343-57, 1981. e-Pub 1981. PMID: 6855633.
360. Mazzone RW, Kornblau S, Durand CM. Shrinkage of lung after chemical fixation for analysis of pulmonary structure-function relations. J Appl Physiol 48(2):382-5, 1980. e-Pub 1980. PMID: 6767671.
361. Mazzone RW, Kornblau S. Size of pores of Kohn: Influence of transpulmonary and vascular pressures. J Appl Physiol 51(3):739-45, 1980. e-Pub 1980. PMID: 6895745.
362. Mazzone RW, Kornblau SM. Pinocytotic vesicles in the endothelium of rapidly frozen rabbit lung. Microvasc Res 21(2):193-211, 1980. e-Pub 1980. PMID: 6261089.
363. Aitken MJL, Malaney P, Zhang X, Herbrich SM, Chan L, Ma H, Jacamo R, Link TM, Kornblau SM, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferative disease in mice via altered Runx1 splicing. Molecular Cell.
364. Hu C, Kornblau SM. Meta-Proteomic Analysis for the Clinic: A Guide Towards Personalized Therapy in Leukemia.
365. Kornblau SM. Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-cell malignancies. Nature.
366. Hoff FW, Griffen T, Kornblau SM, Dijk, van AD. Short commentary on "Histone Modification Patterns Using RPPA‐Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients". Journal of Data Mining in Genomics & Proteomics.
367. Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Hashimoto N, Kojima K, Chachad D, Qiu YH, S-Y Y, Okamoto S, Andreef M, Kornblau SM, Saya H. Loss of Cdh1 initially confers sensitivity to DNA damage but then promotes malignancy in B cell acute lymphoblastic leukemia.
368. Butler M, SchenauDS VI, Yu J, Jenni S, Dobay MP, Hagelaar R, Vervoort BMT, Tee TM, Hoff FW, Meijerink JP, Kornblau SM, Bornhauser B, J-P B, Kuiper RP, van der Meer LT, van Leeuwen FN. Bruton Tyrosine Kinase inhibition sensitizes Acute Lymphoblastic Leukemia to 1 Asparaginase by interfering with the Amino Acid Response pathway. Cancer Discovery.
369. Aitken M, Malaney P, Zhang X, Dijk A, Hubner S, Gallardo M, Kanagal-Shamanna R, Kornblau S, Bueso-Ramos C, Post S. hnRNP K is Overexpressed in Acute Myeloid Leukemia and is Associated with Inferior Outcomes. Cancer Discovery.

Invited Articles

1. Kornblau SM, Konopleva M, Andreeff M. Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opin Investig Drugs 8(12):2027-2057, 1999. e-Pub 1999. PMID: 11139839.
2. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 13(5):1041-57, vii-viii, 1999. e-Pub 1999. PMID: 10553260.

Other Articles

1. Tcheng M, Voisin V, Gronda M, Hurren R, Ling D, Yan Y, Zhang LX, Feng Y, Mancini RS, Currie, Mamai Z, Stock B, Khan S, Jitkova Y, Sarathy C, Ayoub E, Mak PY, Arruda A, Kislinger T, Reed MA, Carter BZ, Andreeff M, Kornblau SM, Vahidi S, Minden MD, Schimmer AD Increased mitochondrial protein import in AML necessitates greater reliance on the mitochondrial unfolded protein response and the mitochondrial LONP1 protease. NATCANCER.
2. Ohanian M, Abruzzo L, Hoff F, Dijik AV, Ruvolo P, Kangal-Shamanna, Gonzalez GN, Andreef M, Post S, Kornblau SM The Prognostic Impact of MYC Protein Expression in Acute Myeloid Leukemia. Blood.
3. Kornblau SM Venetoclax in combination with 10-day decitabine in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. Leukemia.
4. Kornblau SM Ribosome biogenesis and its regulation by the exportin, CSE1L, are selective dependencies in childhood and young adult acute myeloid leukemia. Sci. Transl. Med.
5. Kornblau SM Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia.
6. Hoff FW, Sriraja L, Qiu Y, Jenkins GN, Teachey DT, Wood B, Devidas M, Shockley S, Loh ML, Petsalaki E, Kornblau SM, Horton AM The Proteomics of T-Cell and Early T-Cell Precursor (ETP) Acute Lymphocytic Leukemia: Prognostic Patterns in Adult and Pediatric-ETP ALL. Cancers 16(24):4241, 2024. PMID: 39766140.
7. Kornblau SM Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series, 2024. PMID: 39149601.
8. Kovalenko I, Swamanathan M, Morse D, Ciurea AM, Muhaj FF, Torres-Cabala C, Kornblau SM Temporal Dynamics and Efficacy of CAR-T Cell Therapy in B-ALL with Extramedullary Cutaneous Involvement: A Case Report and Discussion, 2023.
9. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. PMID: 29682723.
10. Alousi A, Ghosh S, Rice D, Moran C, Manning JT, Iliescu C, Hymes S, Kim S, Bashoura L, Kornblau S, Dickey BF Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation. BMJ Case Rep 2011, 2011. PMID: 22707568.
11. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, Tafuri A, Andreeff M Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 11(21):2779-95, 2005. PMID: 16101455.
12. Milella M, Kornblau SM, Andreeff M The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 7(2):160-90, 2003. PMID: 14763161.
13. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno N, Giralt S Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 27 Suppl 2:S13-22, 2001. PMID: 11436116.
14. Deng X, Kornblau SM, Ruvolo PP, May WS Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr(28):30-7, 2001. PMID: 11158204.
15. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111(1):18-29, 2000. PMID: 11091179.
16. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 19(2):118-29, 2000. PMID: 10699539.
17. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 11(2):87-95, 1999. PMID: 10188072.
18. Kornblau SM The role of apoptosis in the pathogenesis, prognosis, and therapy of hematologic malignancies. Leukemia 12 Suppl 1:S41-6, 1998. PMID: 9777895.
19. Wadler S, Benson AB, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16(9):3169-78, 1998. PMID: 9738589.
20. Copeland AR, Bueso-Ramos C, Liu FJ, Kornblau SM, Huh YO, Albitar M Molecular study of hairy cell leukemia variant with biclonal paraproteinemia. Arch Pathol Lab Med 121(2):150-4, 1997. PMID: 9126043.
21. Kornblau SM, Cortes-Franco J, Estey E Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia 7(3):441, 1992. PMID: 8445943.
22. Kornblau SM, Goodacre A, Cabanillas F Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. Hematol Oncol 9(2):63-78, 1991. PMID: 1869243.

Abstracts

1. Bouligny I, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo C, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Kantarjian H, Garcia-Manero G. A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. Clinical Cancer Research, 2024.
2. Yoshimura S, Li Z, Gocho Y, Yang W, Crews KR, Lee SHR, Roberts KG, Mullighan CG, Relling MV, Antillon-Klussmann F, Yeoh AEJ, Loh ML, Litzow MR, Jeha S, Karol ES, Inaba H, C-H P, Konopleva MY, Jain N, Stock W, Paietta E, Jabbour E, Kornblau SM, Evans WE, Yang JJJ. The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia. Blood 142, 2023. e-Pub 2023. PMID: 39102629.
3. Bazinet A, Garcia-Manero G, Short NJ, Alvarado Valero Y, Abuasab T, Islam R, Montalbano K, Issa GC, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau SM, Jabbour EJ, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia TM, Daver N, Konopleva M, Kantarjian HM, Ravandi F. A Phase 2 Study of the Fully Oral Combination of ASTX727 (Dcitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia. Blood 142, 2023. e-Pub 2023.
4. Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Alvarado Valero Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Loghavi S, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Daver N. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Blood 142, 2023. e-Pub 2023.
5. Kim YJ, Li Z, Maiti A, Tanaka T, Uryu H, Furudate K, Hayes K, Daver N, Pemmaraju N, Kadia TM, Ravandi F, Short NJ, Ohanian M, Borthakur G, Jain N, Issa GC, Masarova L, Kornblau SM, Wierda WG, Loghavi S, Wang SA, Garcia-Manero G, Kantarjian H, DiNardo CD, Konopleva MY, Takahashi K. Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms. Blood 142, 2023. e-Pub 2023.
6. Chakraborty S, Morganti C, Dey J, Zhang H, Aluri S, Gitego N, Pradhan K, Rivera B, Chutake Y, Skwarska A, Mantzaris I, Goldfinger M, Feldman EJ, Choudhary GS, Hubner S, Qiu Y, Brown BD, Verma A, Gavathiotis E, Konopleva MY, Kornblau SM, Gollob J, Ito K, Shastri A. A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia. Blood 142, 2023. e-Pub 2023.
7. de Camargo Magalhaes ES, Hubner S, Brown BD, Qiu YH, Kornblau SM. Proteomic Profiking Identifies Unique IDH Mutant Signatures and Novel Therapeutic Opportunities in Adult Acute Myeloid Leukemia Patients. Blood 142, 2023. e-Pub 2023.
8. Urrutia S, Chien KS, Li Z, Borthakur G, Alvarado Valero Y, Kadia TM, Kornblau SM, Daver N, Ravandi F, Bose P, Yilmaz M, Ohanian M, Kanagal-Shamanna R, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero G. Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria. Blood 142, 2023. e-Pub 2023.
9. de Camargo Maglhaes ES, Hubner S, Brown BD, Qiu YH, Kornblau SM. Optimizing FLT Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics. Blood 142, 2023. e-Pub 2023.
10. Kimura S, Pölönen P, Montefiori L, Mullighan CG, et al. STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young. Blood 142, 2023. e-Pub 2023.
11. Sabino de Camargo Magalhaes E, Brown BD, Hubner S, Qiu Y, Kornblau SM. Proteomics-Based Strategy for the Recommendation of Conventional Chemotherapy Vs Venetoclax Plus Hypomethylating Agents in Adult Acute Myeloid Leukemia (AML). Blood 140, 2022. e-Pub 2022.
12. Sabino de Camargo Magalhaes E, Qiu Y, Kornblau SM. Epigenetic Landscape Predicts Overall Survival and Remission Duration in Adult Acute Myeloid Leukemia. Blood 140, 2022. e-Pub 2022.
13. Eagan G, Hurren R, Sarathy C, Thomas GE, Khan DH, Yan Y, Feng Y, Brown B, Kornblau SM, Schimmer AD. The Exportin, XPO2, Is a Novel Therapeutic Target in Pediatric, Adolescent and Young Adult AML. Blood 140:11504-11505, 2022. e-Pub 2022.
14. Barnett KR, Diedrich JD, Bergeron BP, Yang W, Crews KR, Stock W, Paietta E, Kornblau SM, Inaba H, Jeha S, Pui, C-H Relling MV, Evans WE, Yang JJJ, Savic D. Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes. Blood 140, 2022. e-Pub 2022.
15. Hoff FW, Sriraja L, Qiu Y, Jenkins G, Ligerald A, Teachey DG, Wood BL, Devidas M, Loh ML, Alonzo TA, Qutub AA, Petsalaki E, Kornblau SM, Horton TM. RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome. Blood 140, 2022. e-Pub 2022.
16. Desikan SP, Konopleva M, Takahashi K, Lachowiez CA, Loghavi S, L-C X, Kadia TM, Daver N, Short N, Sasaki K, Borthakur G, Issa GC, Maiti A, Chien KS, Alvarado Y, Montalban-Bravo G, Masarova L, Yilmaz M, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian H, DiNardo CD. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia. Blood 140, 2022. e-Pub 2022.
17. Duong N, Khan DH, Thomas GE, Hurren R, Lee JB, St-Germain J, Drimmer LYan Y, MacLean N, Gronda M, Brown BD, Raught B, Arruda A, Minden MD, Zhang L, Kornblau SM, Spadevecchio V, Schimmer AD. Intracellular IL-23 Receptor (IL-23R) Is Necessary for AML Viability and Regulates Mitotic Spindle and Centrosome Formation. Blood 140, 2022. e-Pub 2022.
18. Reville PK, MD, MPH, Kantarjian H, MD, Borthakur G, MD, Yilmaz M, MD, Daver N, MDShort N, DiNardo CD, Kornblau SM, Pemmaraju N, Jain N, Alvarado Y, Bose P, Jabbour E, Chien KS, Abbas HA, Masarova L, Wang SA, Tidwell RSS, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 140, 2022. e-Pub 2022.
19. Bhattarai KR, Barnett KR, Mobley RJ, Ferguson DC, Diedrich JD, Bergeron BP, Yang W, Crews KR, Stock W, Paietta E, Kornblau SM, Hiroto Inaba H, Jeha S, C-H P, Cheng C, Relling MV, Evans WE, Yang JJJ, Savic D. Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment. Blood 140, 2022. e-Pub 2022.
20. Champlin RE, Lustig EB, Bashir Q, Oran B, Kornblau SM, Hosing C, Alousi AM, Popat UR, McCarty JM, Thall PF, Dabaja BS, W-H L, Dang G, Castro K, Ramirez A, Spiotto M, Wu S, Fang P, Kaur I, Rezvani K, Shpall EJ, Reisner Y. First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). Blood 140, 2022. e-Pub 2022.
21. Short NJ, Jabbour E, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, Daver N, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob J, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Kantartian H. The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II StudyClinically Relevant Abstract. Blood 140, 2022. e-Pub 2022.
22. Hubner S, Konopleva M, Zeng Z, Hoff FW, Qiu Y, Ruvolo V, Horton TM, Kornblau SM. Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML). Blood 140, 2022. e-Pub 2022.
23. Abuasab T, Garcia-Manero G, Short N, Alvarado Y, Issa GC, Islam R, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau SM, Jabbour E, Pemmaraju N, Montalban-Bravo G, Pierce SA, DiNardo CD, Kadia TM, Daver N, Konopleva M, Kantarjian H, Ravandi F. Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy. Blood 140, 2022. e-Pub 2022.
24. Barnett KR, Diedrich JD, Bergeron BR, Yang W, Crews KR, Stock W, Paietta EM, Kornblau SM, Inaba H, Jeha S, C-H P, Relling MV, Evans WE, Yang JJ, Savic D. Chromatin Accessibility Landscapes of Acute Lymphoblastic Leukemia. Blood 138, 2021. e-Pub 2021.
25. Short NJ, Kantarjian H, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, Daver N, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob J, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Jabbour EJ. Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 138, 2021. e-Pub 2021.
26. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver N, Jabbour EJ, Kadia TM, Estrov ZE, Kornblau SM, Andreeff M, Cortes JE, Borthakur, G Alvarado Y, Huynh-Lu J, Nguyen-Cao MM, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Allison M Pike AM, Garcia-Manero G, Kantarjian H, Verstovsek S. Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated MyelofibrosisClinically Relevant Abstract. Blood 138, 2021. e-Pub 2021.
27. Abuasab T, Kantarjian H, Garcia-Manero G, Montalban-Bravo G, Alvarado Y, Yilmaz M, Pemmaraju N, Chien KS, Mohamed SF, Daver N, Kornblau SM, Burger JA, Jain N, Islam R, DiNardo CD, Borthakur G, Ravandi F, Kadia TM. Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML). Blood 138, 2021. e-Pub 2021.
28. Lachowiez C, DiNardo CD, Takahashi K, Loghavi S, L-C X, Kadia TM, Daver N, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban-Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau SM, Ravandi F, Jabbour EJ, Konopleva M, Kantarjian H. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid LeukemiaClinically Relevant Abstract. Blood 138, 2021. e-Pub 2021.
29. Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour EJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch J, Kantarjian H, Konopleva M. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic SubgroupsClinically Relevant Abstract. Blood, 2021. e-Pub 2021.
30. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson PA, Toro E, Ruiz K, Burger JA, Wierda WG, Kornblau SM. Proteomic Profiling Based Classification of CLL Provides Prognostication for Modern Therapy and Identifies Novel Therapeutic Targets. Blood 138, 2021. e-Pub 2021.
31. Brown B, Qiu Y, Hoff FW, Kornblau SM. Protein Expression Signatures Predict Response, Relapse, and Survival after Venetoclax Containing Therapy in Adults with Acute Myeloid Leukemia. Blood 138, 2021. e-Pub 2021.
32. Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, NShort NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) – RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood, 2021. e-Pub 2021.
33. Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour EJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch J, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II TrialClinically Relevant Abstract. Blood 138, 2021. e-Pub 2021.
34. Hoff FW, Qiu Y, Brown B, Gerbing RB, Alan S Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins G, Horton TM, Kornblau SM. Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78. Blood 138, 2021. e-Pub 2021.
35. Youn M, Smith SM, Lee AG, H-D C, Spiteri E, Erdmann J, Galperin I, Murphy LC, Donato M, Abidi P, Bittencourt H, Lacayo NJ, Dahl G, Aftandilian C, Davis KL, Matthews JA, Kornblau SM, Huang M, Sumarsono N, Redell M, Fu CH, Chen I-M L, Alonzo TA, Eklund EA, Gotlib J, Khatri P, Sweet-Cordero A, Hijiya N, Sakamoto KM. Gene Expression Analysis of CML Patients across the Age Spectrum. Blood 138, 2021. e-Pub 2021.
36. Short NJ, Kantarjian H, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, Daver N, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob J, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Jabbour EJ. Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 138, 2021. e-Pub 2021.
37. Bazinet A, Jabbour EJ, Kantarjian H, Chien KS, DiNardo CD, Ohanian M, Daver N, Kanagal-Shamanna R, Kadia TM, Takahashi K, Masarova L, Short NJ, MD, Alvarado Y, Thompson PA, Montalban-Bravo G, Yilmaz M, Ravandi F, Kornblau SM, Pemmaraju N, Schneider H, Mirabella B, Naqvi K, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 138, 2021. e-Pub 2021.
38. Alwash Y, Kanagal-Shamanna R, Guerra VA, Daver N, Konopleva M, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Borthakur G, Loghavi S, Takahashi K, Yilmaz M, Maiti A, Kantarjian HM, Kornblau SM, Short NJ. Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. Blood 136, 2020. e-Pub 2020.
39. Baran N, Lodi A, Dhungana Y, Sweeney SR, Renu P, Herbrich S, Hoff FW, Skwarska A, Kaplan M, Kuruvilla VM, Cavazos A, Warmoes M, Rojas-Sutterlin S, Haman A, PhD, Veiga DT, Furudate K, Ma H, Harutyunyan K, Yang W, Gagea M, Du D, Daher M, Garcia LM, Piya S, Ruvolo V, Shanmugavelandy S, Feng N, Gay JP, Havranek O, Henderson J, Tomczak K, Kaminski M, PhD, Herranz D, Ferrando A, Jabbour E, Di Francesco ME, Teachey DE, Horton TM, Rezvani K, Yang JJ, Kornblau SM, Davis E, Takahashi K, Andreeff M, Marzsalek JR, Lorenzi P, Yu J, Tiziani S, Hoang T, Konopleva M. Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. Blood 136, 2020. e-Pub 2020.
40. Carter BZ, Mak PY, Tao W, Ruvolo V, Zhang X, Nishida Y, Kornblau SM, Hughes P, Chen X, Morrow PK, Andreeff M. Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML. Blood 136, 2020. e-Pub 2020.
41. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Takahashi K, Ning J, Ding M, Matthews JA, Little L, Zhang J, Basu S, DiNardo CD, Kadia TM, Ravandi F, Borthakur G, Konopleva M, Garcia-Manero G, Green MR, Alatrash G, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Futreal PA, Daver N. Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. Blood 136, 2020. e-Pub 2020.
42. Youn M, H-D C, Smith SM, Lee AG, Murphy LC, Donato M, Sweet-Cordero A, Abidi P, Bittencourt H, Lacayo NJ, Dahl G, Aftandilian C, Davis KL, Matthews JA, Kornblau SM, Huang M, Sumarsono N, Redell M, Fu CH, I-ML C, Alonzo TA, Eklund EA, Gotlib J, Khatri P, Hijiya N, Sakamoto KM. Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Blood(136), 2020. e-Pub 2020.
43. Daver N, Basu S, Garcia-Manero G, Abbas HA, Konopleva M, Kadia TM, DiNardo CD, Borthakur G, Alotaibi AS, Pemmaraju N, Jabbour E, Pierce SA, Brandt M, Takahashi K, Ning J, Kornblau SM, Sasaki K, Yilmaz M, Issa GC, Short NJ, Matthews JA, Flores W, Andreeff M, Cortes JE, Ravandi F, Allison JP, Kantarjian HM, Sharma P. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. Blood 136, 2020. e-Pub 2020.
44. Kim K, Konopleva M, DiNardo CD, Borthakur G, Garcia-Manero G, Pemmaraju N, Daver N, Jabbour E, Kornblau SM, Yilmaz M, Ohanian M, Ferrajoli A, Jain N, Short NJ, Rausch CR, Brandt M, Pierce SA, Estrov ZE, Ravandi F, Kantarjian HM, Kadia TM. Urgent Cytoreductive Chemotherapy for Newly Diagnosed Patients with AML Is Safe and Feasible and Facilitates Enrollment on Investigational Clinical Trials. Blood 136, 2020. e-Pub 2020.
45. Short NJ, Kantarjian HM, Patel K, Kornblau SM, Jorgensen JL, Wang SA, Konopleva M, Jain N, Kebriaei P, Yilmaz M, Issa GC, Matthews JA, Noor M, Garris R, Ravandi F, Jabbour E. Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical. Blood 136, 2020. e-Pub 2020.
46. Lachowiez C, Konopleva M, Kadia TM, Daver N, Loghavi S, Wang SA, Adeoti M, Pierce SA, Takahashi K, Short NJ, MD, Sasaki K, Borthakur G, Issa GC, Wierda WG, Pemmaraju N, Montalban Bravo G, Ferrajoli A, Jain N, Masarova L, Yilmaz M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian HM, Dinardo CD. Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood 136, 2020. e-Pub 2020.
47. Short NJ, Kanagal Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris RS, Higgins J, Pratt G, Williams L, Valentine C, Rivera V, Salk J, Radich J, Kantarjian HM, Jabbour EJ. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 136, 2020. e-Pub 2020.
48. Maiti A, Jabbour E, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda WG, Konopleva M, Alvarado Y, Short NJ, Faderl S, O'Brien SM, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Khoury JD, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravand F. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood 136, 2020. e-Pub 2020.
49. Hoff FW, van Dijk AD, Qiu Y, de Bont ES, Kornblau SM, Horton TM. Proteomics in Pediatric Acute Myeloid and T-Cell Lymphoblastic Leukemia: Shared Individual Protein Expression Patterns Co-Cluster into Overall Distinct Combinations. Blood 136, 2020. e-Pub 2020.
50. Reville PK, Kantarjian HM, Borthakur G, Yilmaz M, Montalban-Bravo G, DiNardo CD, Andreeff M, Daver N, Jain N, Kornblau SM, Jabbour E, Short NJ, Alvarado Y, Ohanian M, Bose P, Masarova L, Wang SA, Tidwell RSS, Estrov ZE, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 136, 2020. e-Pub 2020.
51. Guerra VA, Alwash Y, Yuanqing Y, Ramos Perez JM, Richard-Carpentier G, Alotaibi AS, Ahaneku HO, Samra B, Raghunath A, Jain N, Short NJ, Ravandi F, Borthakur G, Ferrajoli A, Sasaki K, Kornblau SM, Estrov ZE, Cortes JE, Kantarjian HM, Garcia-Manero G, Jabbour E, Kadia TM. Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL). Blood 136, 2020. e-Pub 2020.
52. Bose P, Pemmaraju N, Masarova L, Bledsoe SD, Daver N, Jabbour E, Kadia TM, Estrov ZE, Kornblau SM, Andreeff M, Cortes JE, Jain N, Borthakur G, Alvarado Y, Huynh-Lu J, Nguyen-Cao M, Richie MA, Dobbins MHZhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study. Blood 136, 2020. e-Pub 2020.
53. Short NJ, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris RS, Higgins J, Pratt G, Williams L, Valentine C, Rivera V, Salk J, Radich J, Kantarjian HM, Jabbour EJ. Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 136, 2020. e-Pub 2020.
54. van Dijk AD, Hoff FW, Qiu Y, de Bont ES, Bruggeman SWM, Horton TM, Kornblau SM. Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia. Blood 136, 2020. e-Pub 2020.
55. Saxena K, Konopleva M, Bhagat TD, Guerra VA, Maduike R, Tiziani S, Borthakur G, Jabbour E, Pemmaraju N, Kadia TM, Short NJ, Burger JA, Kornblau SM, Daver N, Naqvi K, Cai T, Kuruvilla VM, Kantarjian HM, Garcia-Manero G, Verma A, DiNardo CD. AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis. Blood 136, 2020. e-Pub 2020.
56. Andersson BS, Thall P, Valdez BC, Ma J, Chen J, Ahmed S, Alousi AM, Bashir O, Ciurea SO, Gulbis A, Hosing C, Jones RB, Kawedia J, Kebriaei P, Kornblau SM, Meyers AM, Oran B, Rezvani K, Shah N, Shpall EJ, Parmar S, Popat UR, Nieto Y, Champlin RE. A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 136, 2020. e-Pub 2020.
57. Thomas GE, Egan G, Garcia Prat L, Aaron B, Voisin V, Orouji E, Chin JN, Nachmias B, Kaufmann KB, Hoff FW, Maclean N, Hurren R, Wang X, Gronda M, Arruda A, Minden MD, Bader GD, Kornblau SM, Dick JE, Schimmer AD. The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness. Blood 136, 2020. e-Pub 2020.
58. Maiti A, Kantarjian HM, Popat V, Garcia-Manero G, Konopleva M, Verstovsek S, Andreeff M, Gorthakur G, Kadia T, Daver N, Pemmaraju N, DiNardo CD, Pierce S, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Blood 134, 2019. e-Pub 2019.
59. van Dijk AD, Hoff FW, Qiu Y, Figueroa M, Chandra J, Jabbour E, de Bont ES, Kornblau SM. Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates with Overall Survival and Tyrosine Kinase Inhibitor Sensitivity in Adult ALL. Blood 134, 2019. e-Pub 2019.
60. Kadia TM, Cortes JE, Konopleva MY, Borthakur GM, Pemmaraju N, Daver NG, Montalban Bravo G, Issa GC, Naqvi K, Short NJ, DiNardo CD, Bhalla KN, Jabbour E, Takahashi K, Sasaki K, Kornblau SM, Malla B, Pierce SA, Wang X, Estrov ZE, Andreeff M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 134, 2019. e-Pub 2019.
61. Pourebrahimadabi R, Alaniz Z, Ostermann LB, Luong HA, Montoya RH, Ruvolo PP, Kornblau SM, Khoury JD, Bueso-Ramos CE, Andreeff M. p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development. Blood 134, 2019. e-Pub 2019.
62. Short NJ, Garcia-Manero G, Naqvi K, Kornblau SM, Maiti A, Konopleva M, DiNardo CD, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 134, 2019. e-Pub 2019.
63. Short NJ, Patel K, Albitar M, Franquiz M, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov ZE, Ravandi F. Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis. Blood 134, 2019. e-Pub 2019.
64. Sasaki K, J-M R, Figueroa M, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Estrov ZE, Garris R, Houri R, Nasnas P, DiNardo CD, Naqvi K, Kornblau SM, Montalban-Bravo G, Pemmaraju N, Cortes JE, O'Brien SM, Chandra J, Kantarjian HM, Jabbour E. The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood 134, 2019. e-Pub 2019.
65. Short NJ, Kantarjian HM, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes JE, Konopleva MY Issa GC, Kornblau SM, Garcia-Manero G, Rivera V, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Salk JJ, Prichard J, Radich JP, Jabbour E. Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). Blood 134, 2019. e-Pub 2019.
66. Thomas GE, Egan G, Garcia Prat L, Nachmias B, Chin JM, Hoff FW, Kaufmann K, Hurren R, Gronda M, MacLean N, Wang X, Voisin V, Botham A, Arruda A, Minden MD, Bader GD, Kornblau SM, Dick JE, Schimmer AD. The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness. Blood 134, 2019. e-Pub 2019.
67. Aboudalle I, Konopleva MY, Kadia TM, Naqvi K, Vaughan K, Kurt M, Cavazos A, Pierce SA, Takahashi K, Masarova L, Yilmaz ME, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Cortes JE, Kantarjian HM, DiNardo CD. A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood 134, 2019. e-Pub 2019.
68. Post SM, Ma H, Ruvolo V, Zhang X, Yasuhiro T, Tanaka K, Kozaki R, Yoshizawa T, Cortes JE, DiNardo CD, Konopleva MY, Kornblau SM, Khoury J, Andreeff M, Ruvolo PP. AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells. Blood 134, 2019. e-Pub 2019.
69. An X, Adolacion JR, Alfayez M, Matthews J, Flores W, Kornblau SM, Saeedi A, Basu S, Daver NG, Varadarajan N. Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML. Blood 134, 2019. e-Pub 2019.
70. Jabbour E, Roberts KG, Sasaki K, Zhao Y, Qu C, Gu Z, Jain N, Patel KP, Ravandi F, Short NJ, Garcia-Manero G, Garris R, Kornblau S, Konopleva MY, Mullighan CG, Kantarjian HM. Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood 134, 2019. e-Pub 2019.
71. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Patel KP, Kantarjian HM, Konopleva MY, DiNardo CD. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood 134, 2019. e-Pub 2019.
72. Albitar M, Konopleva MY, Zhang H, De Dios I, Ma W, Antzoulatos S, Kornlbau SM, Cavazos A, Loghavi S, Takahashi K, Kantarjian HM, DiNardo CD. Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia. Blood 134, 2019. e-Pub 2019.
73. Albitar M, Konopleva MY, De Dios I, Estella JJ, Antzoulatos S, Kornblau SM, Cavazos A, Loghavi S, Takahashi K, Kantarjian HM, DiNardo CD. Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia. Blood 134, 2019. e-Pub 2019.
74. Dijk V, AD, Ruvolo PP, Hoff FW, Qiu Y, Gamis AS, Aplenc R, Kolb AE, Alonzo TA, Gerbing RB, de Bont ES, Bruggeman SWM, Horton TM, Kornblau SM. Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children’s Oncology Group Phase 3 Clinical Trial. Blood 134, 2019. e-Pub 2019.
75. Mirali S, Aaron B, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, Jitkova Y, Xu W, Nachmias B, MacLean N, Wang X, Arruda A, Minden MD, Horton TM, Kornblau SM, Chan SM, Bader GD, Raught B, Schimmer AD. ARC-regulated IL1β/Cox-2/PGE2/β-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML. Blood 134, 2019. e-Pub 2019.
76. Maiti A, DiNardo CD, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian MN, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz ME, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, ChenZ, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood 134, 2019. e-Pub 2019.
77. Daver NG, Garcia-Manero G, Konopleva MY, Alfayez M, Pemmaraju N, Kadia TM, DiNardo CD, Cortes JE, Ravandi F, Abbas H, Basu S, Jabbour E, Pierce SA, Estrov ZE, Takahashi K, Ning J, Kornblau SM, Sasaki K, Masarova L, Flores W, Allison JP, Sharma P, Kantarjian HM. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood 134, 2019. e-Pub 2019.
78. Carter BZ, Mak PY, Kornblau SM, Tao W, Nishida Y, Ruvolo V, Cidado J, Drew L, Andreeff M. TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1. Blood 134, 2019. e-Pub 2019.
79. Hoff FW, Qiu Y, Hu W, Qutub AA, de Bont ES, Horton TM, Kornblau SM. Proteomic Landscape of Acute Leukemia: A Comparison between ALL and AML in Adults. Blood 134, 2019. e-Pub 2019.
80. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Patel KP, Kantarjian HM, Konopleva MY, DiNardo CD. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood 134, 2019. e-Pub 2019.
81. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna B, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA Pierce S, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 132, 2018. e-Pub 2018.
82. Van Dijk AD, Hoff FW, de Bont ES, Qiu Y, Hu W, Qutub AA, Horton TM, Kornblau SM. Signatures of Histone Modification Marks and Proteins in Pediatric Acute Myeloid Leukemia: A Comparison to Adults. Blood, 2018. e-Pub 2018.
83. Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Kadia TM, Konopleva MY, Jabbour EJ, DiNardo CD, Assi R, Pierce SA, Alvarado Y, Estrov ZE, Pemmaraju N, Takahashi K, Ning J, Nogueras Gonzalez GM, Kornblau SM, Alfayez M, Matthews J, Flores W, Blando J, Allison JP, Sharma P, Kantarjian HM. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood, 2018. e-Pub 2018.
84. Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, TMl K, Alvarado Y, Jabbour EJ, Konopleva MY, Takahashi K, Kornblau SM, DiNardo CD, Estrov ZE, Flores W, Basu S, Allison JP, Sharma P, Pierce SA, Pike A, Cortes JE, Ravandi F. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood, 2018. e-Pub 2018.
85. Pourebrahim R, Ruvolo PP, Kornblau SM, Bueso-Ramos CE, Andreeff M. Genetic Dissection of p53 Driven Senescence of Bone Marrow Mesenchymal Cells in Acute Myeloid Leukemia. Blood 132, 2018. e-Pub 2018.
86. Bose P, McCue D, Wiederhold NP, Kadia TM, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov ZE, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood, 2018. e-Pub 2018.
87. Short NJ, Kantarajian HM, Sasaki K, Ravandi F, Cortes JE, Konopleva MY, Issa GC, Kanagal-Shamanna R, Kornblau SM, g G, Rivera V, Garris RE, Salk J, Prichard J, Radich JP, Jabbour EJ. Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2018. e-Pub 2018.
88. Hoff FW, Qiu Y, Hu W, Qutub AA, Gamis AS, Aplenc R, Kolb A, Alonzo A, de Bont ES, Horton TM, Kornblau SM. Proteomic Landscape of De Novo Pediatric Acute Myeloid Leukemia. Blood, 2018. e-Pub 2018.
89. Cogle CR, Abbasi T, Singh NK, Sauban M, Raman RK, Vidva R, Tyagi A, Talawdekar AA, Das A, Kornblau SM, Hoff FW, Horton TM, Vali S. AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow. Blood 132, 2018. e-Pub 2018.
90. Mill CP, Cai T, Fiskus W, Borthakur G, Kornblau SM, Kadia TM, DiNardo CD, Nowak AJ, Saenz DY, Saenz DN Sun B, Ganesh T, Jin W, Rao V, Khoury JD, Shen Y, Konopleva MY, Bhalla KN. Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells. Blood, 2018. e-Pub 2018.
91. Hoff FW, Ruvolo PP, Qiu Y, Andreeff M, de Bont ES, Horton TM, Kornblau SM. AXL Expression in Pediatric AML Is Associated with Putative LSC and Correlates with a Distinct Set of Proteins Associated with Cell Metabolism, Cell Cycle, and Unfolded Protein Response. Blood 132, 2018. e-Pub 2018.
92. Hoff FW, Hu W, Qiu Y, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Qutub AA, de Bont ES, Bruggeman SWM, Kornblau SM, Horton TM. RPPA-Profiling Identifies Patients with Low Phosphorylation Levels of HSF1 at Serine 326 As Potential Candidate for Bortezomib Treatment in Addition to Standard Therapy in Pediatric Acute Myeloid Leukemia. Blood, 2018. e-Pub 2018.
93. Rausch CR, Paul S, Montalban-Bravo G, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, Kadia TM, Konopleva MY, Ohanian MN, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood, 2018. e-Pub 2018.
94. Saenz DT, Fiskus W, Manshouri T, Saenz DN, Soldi B, Sun B, Mill CP, Nowak AJ, Kornblau SM, Bose P, Kadia TM, DiNardo CD, Masarova L, Horrigan S, Khoury JD, Sharma S, Verstovsek S, Bhalla KN. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis. Blood, 2018. e-Pub 2018.
95. Mirali S, Aaron B, Voisin V, Qiu Y, Hoff FW, Hurren R, Gronda M, Jitkova Y, Xu GW, MacLean N, Wang X, Horton TM, Kornblau SM, Chan SM, Bader GD, Schimmer A. The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML. Blood, 2018. e-Pub 2018.
96. Alfayez M, Kantarjian HM, Ravandi F, Garcia-Manero G, Konopleva MTY, Daver NG, DiNardo CD, Borthakur G, Bose P, Andreeff M, Alvarado Y, Yilmaz ME, Pemmaraju N, Kornblau SM, Estrov ZE, Benton CB, Takahashi K, Naqvi K, Slack R, Islam R, Jabbour EJ, Je C, Kadia TM. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 132, 2018. e-Pub 2018.
97. Maiti A, DiNardo CD, CortesJE, Pemmaraju N, Benton CB, Kadia TM, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Thompson PA, Kornblau SM, Masarova L, Jain N, Jabbour EJ, Andreeff M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Rausch CA, Bivins CA, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018. e-Pub 2018.
98. Kadia TM, Konopleva MY, Garcia-Manero G, Benton CB, Wierda WG, Bose P, Yilmaz ME, Jabbour EJ, Kornblau SM, Bhalla KN, Pemmaraju N, Jain N, Malla R, Borthakur G, Cortes JE, Ravandi F, Kantarjian HM. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood, 2018. e-Pub 2018.
99. Major CK, Kantarjian HM, Borthakur G, Kadia TM, Pemmaraju N, Short NJ, Daver NG, Jabbour EJ, Champlin RE, Garcia-Manero G, Konopleva MY, Andreeff M, Kornblau SM, Wierda WG, Pierce SA, Ravandi F, Cortes JE. Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). Blood, 2018. e-Pub 2018.
100. Daver NG, Assi R, Kantarjian HM, Cortes JE, Ravandi F, Konopleva MY, Kadia TM, Borthakur G, Jabbour EJ, DiNardo CD, Velasquez M, Kelly M, Ning J, Nogueras Gonzalez GM, Pierce SA, Gombos D, Estrov ZE, Kornblau SM, Zhang W, Andreeff M. Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML). Blood 132, 2018. e-Pub 2018.
101. Hornbaker MJ, Malaney P, Zhang X, Duan R, Shah V, Herbrich S, Gallardo M, Jacamo R, Link T, Ma H, Alybayev S, Kornblau SM, Hu P, Sarbassov D, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1. Blood, 2018. e-Pub 2018.
102. Han L, Qiu P, Jorgensen J, Mak D, Burks J, McQueen T, Zeng Z, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Andreeff M, Guzman ML, Konopleva MY. Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse. Blood, 2018. e-Pub 2018.
103. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Devidas M, Dai Y, Reshmi SC, Foster JG, Raetz EA, Borowiltz MJ, Wood B, Carroll WL, McKay PZ, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich J, Minden MD, Zhang Y, Bhatia R, Kohlschmidt J, Mrozek K, Bloomfield CD, Stock W, Kornblau SM, Kantarjian HM, Konopleva MY, Evans WE, Jeha S, C-H P, Yang JJ, Paietta EM, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG. Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood 132, 2018. e-Pub 2018.
104. Van Dijk AD, Hoff FW, de Bont ES, Qiu Y, Hu CW, Qutub AA, Horton TM, Kornblau SM. Signatures of Histone Modification Marks and Proteins in Pediatric Acute Myeloid Leukemia: A Comparison to Adults. Blood, 2018. e-Pub 2018.
105. Short NJ, Jabbour EJ, RavandiF, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Khoury JD, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz M, Borthakur G, MD, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnas P, Jacob J, Garris RE, O'Brien SM, Kantarjian HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 132, 2018. e-Pub 2018.
106. Montalban-Bravo G, Benton CB, Kanagal-Shamanna R, Sasaki K, Assi R, Kadia TM, Ravandi F, Ganan-Gomez I, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Kornblau SM, Patel K, Colla S, Kantarijan HM, Andreeff M, Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2018. e-Pub 2018.
107. Hoff FW, Ruvolo PP, Qiu YH, Giaccia A, Andreeff M, deBont ES, Horton TM, Kornblau SM. AXL expression in pediatric AML is associated with putative LSC and correlates with a distinct set of proteins associated with cell metabolism, cell cycle, and unfolded protein response. Blood 132, 2018. e-Pub 2018.
108. Hoff FW, Qiu YH, Hu W, Qutub AA, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, de Bont ES, Horton TM, Kornblau SM. Proteomic Landscape of De Novo Pediatric Acute Myeloid Leukemia. Blood, 2018. e-Pub 2018.
109. Roman D, Kantarjian HM, Cortes JE, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Daver NG, Pemmaraju P, Kadia TM, Kornblau SM, Bose P, Andreeff M, Freireich EJ, Ravandi F, Aung FM. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood, 2018. e-Pub 2018.
110. DiNardo CD, Albitar M, Kadia TM, Naqvi K, Vaughan K, Cavazos A, Pierce SA, Takahashi K, Kornblau SM, Ravandi F, Cortes JE, Kantarjian HM, Konopleva MY. Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study. Blood 132, 2018. e-Pub 2018.
111. van Dijk A, Hu W, de Bont ES, Qiu Y, Hoff F, Yoo SY, Coombes KR, Qutub A, Kornblau SM. Histone Modification Patterns Using RPPA-Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients. Blood 130, 2017. e-Pub 2017.
112. Daver N, Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour EJ, DiNardo CD, Kadia T, Ning J, Gonzalez GN, Pierce S, Kelly M, Zhang W, Gombos D, Kornblau SM, Konopleva M, Cortes JE, Kantarjian HM, Andreeff M. a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML). Blood 130, 2017. e-Pub 2017.
113. Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Esrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood 130, 2017. e-Pub 2017.
114. Bansal H, Kornblau S, Qiu Y, Coombes KR, Panneerdoss S, Karnad A, Weitman S, Tomlinson G, Bansal S, Iyer SP. Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia. Blood 130, 2017. e-Pub 2017.
115. Ruvolo PP, Hu C, Qiu YH, Ruvolo V, Coombes KR, Qutub A, Andreeff M, Kornblau SM. Galectin 3 Protein Network Analysis By Reverse Protein Arrays Demonstrates Regulation of MCL-1, PKC Delta and CD74 Associated with Poor Survival in Patients with AML. Blood 130, 2017. e-Pub 2017.
116. Takahashi K, Wang F, Morita K, Yan Y, Patel K, Bueso-Ramos CE, Gumbs C, Zhang J, Kornblau SM, DiNardo CD, Ravandi F, Garcia-Manero G, Jabbour EJ, Andreeff M, Kantarjian HM, Konopleva M, Futreal A. Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia (MPAL). Blood 130, 2017. e-Pub 2017.
117. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau SM, Kadia T, Flores W, Matthews J, NiNardo CD, Borthaku G, Konopleva M, Allison J, Sharma P, Kantarjian HM. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML. Blood 130, 2017. e-Pub 2017.
118. Hoff F, Hu W, Qiu Y, Qutub A, Kornblau SM. Proteomic Profiling Reveals Protein Expression Patterns Correlated with Outcome in Acute Promyelocytic Leukemia (APL). Blood 130, 2017. e-Pub 2017.
119. Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu PC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau SM, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Brandt M, Pike A, Cortes JE, Kantarjian HM. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 130, 2017. e-Pub 2017.
120. Chan LN, Hurtz C, Caesar R, Shojaee S, Xiao G, Geng H, Loh ML, Ye HB, Kornblau SM, Muschen M. BCL6 Enables RAS-Driven Pre-B Cell Transformation in Acute Lymphoblastic Leukemia. Blood 130, 2017. e-Pub 2017.
121. Shrot NJ, Garcia-Manero G, Naqvi K, Kornblau SM, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Chosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130, 2017. e-Pub 2017.
122. Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gaisor Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. Blood 130, 2017. e-Pub 2017.
123. Hornbaker MJ, Gallardo M, Zhang X, Malaney P, Herbrich S, Ma H, Hu P, Kornblau SM, Bueso-Ramos CE, Post SM. hnRNP K: A Driver of Myeloid Malignancy. Blood 130, 2017. e-Pub 2017.
124. Gurguis C, de Armas LR, Kantarjian HM, Boddu PC, Jain P, Korthakur G, Giza DE, Illescu G, Lopez-Mattei J, Kim P, Garcia-Manero G, Ravandi F, Wierda WG, Kornblau SM, Jabbour EJ, Illescu C, Cortes JE. Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML). Blood 130, 2017. e-Pub 2017.
125. Wiliams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Al-Hamal Z, Konopleva M, Ning J, L-C X, Lopez JH, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Alatrash G, Allison JP, Kantarjian HM, Sharma P, Daver N. Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity. Blood 130, 2017. e-Pub 2017.
126. Khan M, Carmona S, Sukhumakchandra P, Qiu Y, Perakis A, Zhang M, Zope M, Philip A, Shah A, Qiao N, St John L, Goldberg J, Mittendorf E, Molldrem JJ, Kornlbau SM, Alatrash G. Cathepsin G Is Expressed By B Cell Acute Lymphoblastic Leukemia and Is an Effective Immunotherapeutic Target. Blood 130, 2017. e-Pub 2017.
127. Daver N, Boddu P, Garcia-Manero G, Ravandi F, Jabbour EJ, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Kida T, Jain N, Pierce S, Flores W, Kornblau S, Hussain N, Ning J, Gonzalez GN, Basu S, Cortes JE, Sharma P, Kantarjian HM. Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML. Blood 130, 2017. e-Pub 2017.
128. Maiti A, Kantarjian HM, Popat V, Garcia-Manero G, Konopleva M, Verstovsek S, Andreeff M, Gorthakur G, Kadia T, Daver N, Pemmaraju N, DiNardo CD, Pierce S, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?. Blood 130, 2017. e-Pub 2017.
129. Bansal S, Kornblau SM, Qiu YH, Subbarayal U, Coombes K, Porio D, Karnad K, Weitman H, Spiyer A, Tomlinson G. Overexpression of BRD4 is An Independent Adverse Prognostic Factor in Acute Myeloid Leukemia. Haematologica, 2017.
130. Abaza Y, Kantarjian HM, Jabbour EJ, Thomas DA, Kadia TM, Borthakur G, Burger J, Wierda WG, Jain N, Faderl S, O'Brien SM, Konopleva M, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Prithviraj Bose P, Thompson PA, Kelly MA, Garris R, Garcia-Manero G, Cortes JE, Ravandi F. Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 128(22), 2016. e-Pub 2016. PMID: 29047158.
131. Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Brandt M, Pierce S, gM N, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood 128(22), 2016. e-Pub 2016.
132. Benton CB, Takahashi K, Bose P, Wang F, H-C C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour EJ, DiNardo CD, MD, Bueso-Ramos CE, Patel K, Kornblau SM, Konopleva M, Borthakur G, Kadia TM, Cortes JE, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian HM. Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood 128(22), 2016. e-Pub 2016.
133. Hoff FW, Hu CW, Qiu YH, S-Y Y, Qutub A, de Bont ES, Horton TM, Kornblau SM. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Suggests New Therapeutic Targets. Blood 128(22), 2016. e-Pub 2016.
134. Garcia-Manero G, Daver NG Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128(22), 2016. e-Pub 2016.
135. Hornbaker MJ, Gallardo M, Zhang X, Ma H, Hu P, Khoury JD, Kornblau SM, Bueso-Ramos CE, Post SM. hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation. Blood 128(22), 2016. e-Pub 2016.
136. Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y Richie MA Pierce S, Jabbour EJ, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood 128(22), 2016. e-Pub 2016.
137. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia TM, Cortes JE, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Patel KP, Kornblau SM, Kantarjian HM, Young KH, Garcia-Manero G, Andreeff M. Pure Erythroid Leukemia Is Characterized By TP53 mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. Blood 128(22), 2016. e-Pub 2016.
138. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Lopez J, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Allison J, Kantarjian HM, Sharma P. Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). Blood 128(22), 2016. e-Pub 2016.
139. Boddu PC, Kantarjian HM, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia TM, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau SM, Dellasala SE, Pierce S, Jabbour EJ, Cortes JE. Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. Blood 128(22), 2016. e-Pub 2016.
140. Sasaki K, Jabbour EJ, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, Kadia TM, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DiNardo CD, Jain N, Benton CB, Takahashi K, Naqvi K, Bose P, Kornblau SM, Andreeff M, Keating MJ, Freireich EJ, Kantarjian HM. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22), 2016. e-Pub 2016.
141. Jain N, Roberts KG, Jabbour EJ, Patel K, Eterovic K, Fawcett G, Zweidler-McKay P, Lu X, Wang S, Konoplev S, Harvey RC, I-M C, Payne-Turner D, Valentine M, Thomas DA, Garcia-Manero G, Ravandi F, JEl C, Kornblau SM, O'Brien SM, Pierce S, Jorgensen JL, Shaw K, Willman CL, Mullighan C, Kantarjian HM, Konopleva M. 1082 High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy. Blood 128(22), 2016. e-Pub 2016.
142. Short NJ, Garcia-Manero G, Naqvi K, Kornblau SM, Maiti A, Konopleva M, DiNardo CD, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 128(22), 2016. e-Pub 2016.
143. Daver N, i Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, Hidalgo Lopez JE, Allison J, Kantarjian HM, Sharma P. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood 128(22), 2016. e-Pub 2016.
144. Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau SM, Ohanian M, Pierola AA, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero G. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128(22), 2016. e-Pub 2016.
145. J-W L, Geng H, Chen Z, Klemm L, Cosgun KN, Xiao G, Masouleh B, Hurtz C, Parekh S, Kornblau SM, Melnick A, Abbas A, Paietta E, Müschen M. CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. Blood 128(22), 2016. e-Pub 2016.
146. Hoff FW, Hu CW, Qiu YH, S-Y Y, Qutub A, Horton TM, Kornblau SM. Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Blood 128(22), 2016. e-Pub 2016.
147. Q-U S, L-w D, K-T T, Chien W, Mayakonda A, Yeoh AE, Kawamata N, Nagata Y, Jin-Fen X, X-Y L, D-C L, Carg M, Y-Y J, Xu L, S-L L, L-Z L, Madan V, Sanada M, Fernandez LT, Preethi H, Lill M, Kantarjian HM, Kornlbau SM, Miyano S, D-C L, Ogawa S, L-Y S, Yang H, Koeffler HP. Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Blood 128(22), 2016. e-Pub 2016.
148. Ohanian M, Kantarjian HM, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt JR, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood 128(22), 2016. e-Pub 2016.
149. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Borthakur G, Pemmaraju N, Bueso-Ramos CE, Lopez JEH, Blando J, Allison J Kantarjian HM, Sharma P. Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood 128(22), 2016. e-Pub 2016.
150. Ragon BK, Hoff FW, Hu CW, Qiu YH, S-Y Y, Qutub A, Kornblau SM. Functional Proteomic Profiling of Myelodysplastic Syndromes Reveals Distinct Protein Expression Signatures and Identifies Candidate Therapeutic Targets. Blood 128(22), 2016. e-Pub 2016.
151. Abaza Y, Kantarjian HM, Jabbour EJ, Thomas DA, Kadia TM, Borthakur G, Burger J, Wierda WG, Jain N, Faderl S, O'Brien SM, Konopleva M, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Prithviraj Bose P, Thompson PA, Kelly MA, Garris R, Garcia-Manero G, Cortes JE, Ravandi F. Phase II Study of Hyper-CVAD plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. JCO, 2016.
152. Ravandi F, Cortes JE, Garcia-Manero G, Estey E, Borthakur G, Jabbour EJ, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, Kornblau SM, Kadia T, Daver N, DiNardo C, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, Kantarjian HM. Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood 126(23), 2015. e-Pub 2015.
153. Zhang J, McCastlain K, Qu C, Wu G, Edmonson M, Li Y, Wei L, Payne-Turner D, Yoshihara H, Churchman ML, Waanders E, Ntziachristos P, Aifantis L, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Xiang C, Rusch M, Boggs K, Vadodaria B, Dalton J, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Evans WE, C-H P, Jeha S, Harvey RC, Chen I-M L, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrozek K, Paietta E, Tallman MS, Stock W, Voorhees PM, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Hunger SP, Loh ML, Down JR, Mullighan CG. Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood 126(23), 2015. e-Pub 2015.
154. Zeng Z, Liu W, Tsao T, Qiu Y, Samudio I, Baggerly K, Kornblau SM, Kantarjian HM, Andreeff M, Konopleva M. Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant. Blood 126(23), 2015. e-Pub 2015.
155. Ruvolo P, Qiu Y, Ruvolo V, R-Y W, Zeng Z, Burks J, Pan R, Hail Jr N, McQueen T, S-Y Y, Kornblau SM, Andreeff M. Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment. Blood 126(23), 2015. e-Pub 2015.
156. Kornblau SM, Ruvolo PP, R-Y W, Ruvolo VR, Qiu YH, Battula L, Zeng Z, McQueen T, S-Y Y, Konopleva M, Andreeff M. Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC. Blood 23, 2015. e-Pub 2015.
157. Gallardo M, Lee HJ, Zhang X, Bueso-Ramos CE, Pageon L, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Hu P, Qi Y, Su X, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. Blood 126(23), 2015. e-Pub 2015.
158. Kadia T, Ravandi F, Daver N, Borthakur G, Cortes JE, Jabbour E, Kornblau SM, Verstovsek S, Weida W, Burger JA, Estrov Z, DiNardo C, Dong XQ, Pemmaraju N, Ohanian M, Takahashi K, Hendrickson S, Kantarjian H, Garcia-Manero G. Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia. Blood 126(23), 2015. e-Pub 2015.
159. Carter BZ, Kornblau SM, Mak PY, Yang H, Qiu Y, Jiang X, Coombes K, Zhang N, Garcia-Manero G, Andreeff M. Focal Adhesion Kinase As a Potential Target in AML and MDS. Blood 126(23), 2015. e-Pub 2015.
160. Chan LN, Chen Z, Braas D, Geng H, Hurtz C, Shojaee S, Cazzaniga V, Ng C, Ernst T, Hochhaus A, Kornblau SM, Cazzaniga G, Liu G, Milne T, Koeffler HP, Armstrong SA, Dickins RA, Yamamoto KR, Graeber TG, Muschen M. B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling. Blood 126(23), 2015. e-Pub 2015.
161. J-W L, Chen Z, Geng H, Xiao G, Park E, Parekh S, Kornblau SM, Melnick A, Abbas A, Paietta E, Muschen M. CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. Blood 126(23), 2015. e-Pub 2015.
162. Brown F, Still E, Cifani P, Ficarro S, Pouliot G, Drill E, Gonen M, He J, Balasubramanian S, Zhong S, Pavlick D, Yilmazel B, Krivtsov AV, Alonzo TA, Meshinchi S, Kornblau SM, Rm S, Marcucci G, Byrd JC, Levine RL, Armstrong SA, Gray N, Marto J, Kentsis A. Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. Blood 126(23), 2015. e-Pub 2015.
163. Ruvolo PP, Battula VL, Qui YH, Ruvolo VR, Jacamo R, Zeng Z, R-Y W, McQueen T, Rao A, Yoo SY, Le PM, Jr H, N, Carter BZ, Kornblau SM, Andreeff M. Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling. Blood, 2014. e-Pub 2014.
164. Kornblau SM, Hu CW, Qiu YH, Yoo SY, Nguyen TT, Kadia T, Borthakur G, Coombes K, Qutub AA. Heatshock Protein (HSP) Family Expression Is Dichotomous and Prognostic in Acute Myelogenous Leukemia (AML). Blood, 2014. e-Pub 2014.
165. Thomas DA, O'Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger JA, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, Kadia T, Garris R, Pemmaraju N, Daver N, Jain N, Cortes J, Kantarjian HM. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2014. e-Pub 2014.
166. Geng H, Hurtz C, Baumjohann D, Chen Z, W-Y C, Ballabio E, Xiao G, J-W L, Deucher A, Qi Z, Huang C, Nahar R, S-m K, Shojaee S, Chan LN, Yu J, Tyner JW, Chang BH, Kornblau SM, Bijl JJ, Ye H, Paietta E, Melnick A, Roeder R, Hunger S, Loh M, Milne T, Muschen M. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. Blood, 2014. e-Pub 2014.
167. Nishida Y, Kojima K, Maeda A, Chachad D, Kitamura H, Ishizawa J, Andreeff M, Kornblau SM, Kimura S. Prognostic Impact and Targeting of BMI-1 in Acute Myeloid Leukemia. Blood, 2014. e-Pub 2014.
168. Kornblau SM, Hu CW, Qiu YH, Yoo SY, Murray RA, Jain N, Alvarado Y, Coombes K, Qutub AA. Expression of Ribosomal Protein S6 (R6SP) and Eukaryotic Translation Initiation Factor 4E Binding Protein 1 (EIF4EBP1) Is Correlated in Acute Myelogenous Leukemia (AML) and Is Highly Prognostic, Especially in NPM1 and FLT3 Wildtype Patients. Blood, 2014. e-Pub 2014.
169. Perez-Andreu V, Roberts KG, Heng X, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, I-M C, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcuccci G, Bloomfield CD, Mrozek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, C-H P, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ. A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014. e-Pub 2014.
170. Al-Alatrash G, Zhang M, Sukhumalchandra P, Qiu YH, Talukder AH, Senyukov V, St John LS, He H, Sergeeva A, Roszik J, Clise-Dwyer K, Lu S, Ma Q, Mittendorf EA, Lee DA, Hawke DH, Gregory L, Molldrem JL, Kornblau SM. Cathepsin G is Broadly Expressed By AML and Is an Effective Immunotherapeutic Target Against AML in Vivo. Blood, 2014. e-Pub 2014.
171. Naval D, Cortes JE, Jabbour E, Pemmaraju N, Jain N, Estrov Z, Kornblau SM, Burger JA, Kantarjian HM, Newberr KJ, Verstovsek S. Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis. Blood, 2014. e-Pub 2014.
172. Gallardo M, Lee HJ, Zhang X, Pageon LR, Multani A, Reschke M, Clohessy JG, Quintas-Cardama A, Andreeff M, Kornblau SM, Pandolfi PP, Post SM. hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood, 2014. e-Pub 2014.
173. Zeng Z, R-Y W, Shi Y, Qiu YH, Mak DH, Coombes K, Yoo SY, Jessen K, Liu Y, Rommel C, Kantarjian HM, Kornblau SM, Fruman D, Andreeff M, Konopleva M. MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML. Blood, 2014. e-Pub 2014.
174. Pinnamaneni P, Jorgensen JL, Kantarjian HM, Jabbour E, Pierce SR, Brandt M, Wang SA, Konoplev S, Konopleva M, Kornblau SM, Kadia T, DiNardo CD, Pemmaraju N, Andreeff M, Estrov Z, Garcia-Manero G, Cortes JE, Ravandi F. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. Blood, 2014. e-Pub 2014.
175. Shojaee S, Cazzaniga V, Schjerven H, Buchner M, Hurtz C, Geng H, Hochhaus A, Cazzaniga G, Melnick AM, Kornblau SM, Graeber TG, Muschen M. PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells. Blood, 2014. e-Pub 2014.
176. Kampen KR, Scherpen FJG, Kornblau SM, de Bont SJM. p53 Suppression Mediates Blasts Survival, Proliferation and CD34 Maintenance in Pediatric Acute Myeloid Leukemia. Blood, 2014. e-Pub 2014.
177. Cheng X, Byrne MT, Brown K, Konopleva M, Kornblau SM, Bennett RL, May WS. PKR Inhibits the DNA Damage Response and Correlates with Poor Clinical Outcomes in AML. Blood, 2014. e-Pub 2014.
178. Lacobucci I, Roberts KG, Li Y, Payne-Turner D, Valentine M, Zhang J, Harvey RC, McCastlain K, Easton J, Chen I-M L, Rusch M, Kornlbau SM, Konopleva M, Paietta EM, Rowe JM, C-H P, Gastier-Foster J, Loh M, Willman CL, Downing JR, Hunger S, Mullighan CG. Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014. e-Pub 2014.
179. Kornblau SM. CREB/ATF Family Protein Expression States in AML: Active CREB1, but Not ATF Is an Adverse Prognostic Factor. Blood, 2014. e-Pub 2014.
180. Horton TM, Qiu YH, Jenkins G, Kornblau SM. Protein Expression Clusters Can Differentiate Leukemia Subtypes in Pediatric Leukemia. Blood, 2014. e-Pub 2014.
181. Eckstein OS, Wang L, Punia J, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA. Mixed Phenotype Acute Leukemia (MPAL) Has a High Frequency of Mutations in Epigenetic Regulatory Genes: Results from Whole Exome Sequencing. Blood, 2014. e-Pub 2014.
182. Tabe Y, Hatanaka Y, Ruvolo PP, Miida T, Kornblau SM, Andreeff M, Konopleva M. Pro-Survival Effects of TGF-β1 Are Associated with Molecular Signaling Changes of ERK, FLI-1, and CD44 in AML Cells. Blood, 2014. e-Pub 2014.
183. Gallardo M, Lee HJ, Burso-Ramos CE, Zhang X, Pageon LR, Multani A, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K: A Tumor Suppressor or Oncogene?. Blood, 2014. e-Pub 2014.
184. Mak PY, Kornblau SM, Qiu Y, Wei W, Kouji H, Coombes K, Cortes J, Andreeff M, Carter BZ. Disrupting Wnt/ß-Catenin Signaling By a ß-Catenin/CBP Modulator C-82 Suppresses Cell Growth and Induces Apoptosis in AML Blasts and CD34+38- AML Progenitor Cells. Blood, 2014. e-Pub 2014.
185. Seyedmehdi S, Chen Z, Buchner M, Hurtz C, Geng H, Schjerven H, Chan LN, Koeffler P, Willman CL, Hunger S, Dovat S, Paietta E, W-K H, Melnick AM, Alexander WS, Kornblau SM, Muschen M. Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2014. e-Pub 2014.
186. Geng H, J-W L, Chen Z, Masouleh BK, Hurtz C, Park E, Xiao G, Parekh S, Kornblau SM, Melnick A, Paietta E, Muschen M. IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. Blood, 2014. e-Pub 2014.
187. Jain P, Kantarjian HM, Jabbour E, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau SM, Ravandi F, O'Brien S, Cortes J. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2014. e-Pub 2014.
188. Mahumud H, Bezouzi P, ter Elst A, Scherpen FJG, Kampen KR, De Haas V, Guryev V, Peppelenbosch MP, Johannes F, Kornblau SM, Bont E. Kinomic Profiling of Pediatric Acute Myeloid Leukemia for Detailed Cellular Insights. Blood, 2014. e-Pub 2014.
189. Hu CW, Kornblau SM, Bisberg A, Qutub AA. Standard Proteomic Analysis (SPA) in AML: An Integrated Procedure for Discovering Hypoxia and Angiogenesis Paterns. Blood, 2014. e-Pub 2014.
190. Geng H, Hurtz C, Baumjohann D, Chen Z, W-Y C, Ballabio E, Xiao G, J-W L, Deucher A, Qi Z, Huang C, Nahar R, S-m K, Shojaee S, Chan LN, Yu J, Tyner JW, Chang BH, Kornblau SM, Bijl JJ, Ye H, Paietta E, Melnick A, Roeder R, Hunger S, Loh M, Milne T, Muschen M. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. Blood, 2014. e-Pub 2014.
191. Hu C, Qutub A, Qiu YH, Yoo SK, Zhang N, Daver N, Ohanian S, Coombes KR, Kornblau SM. Adhesion Signaling States in AML. Blood, 2014. e-Pub 2014.
192. Daver N, Kantarjian H, BeBose L, Jabbour E, Borthakur G, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo C, Ravandi F, Cortes J, Andreeff M, Konopleva M. BUPARLISIB, A PI3K INHIBITOR, DEMONSTRATES ACCEPTABLE TOLERABILITY AND PRELIMINARY ACTIVITY IN A PHASE I/II TRIAL OF PATIENTS WITH ADVANCED LEUKEMIAS. EHA Conference, Milano Italy, 2014. e-Pub 2014.
193. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Cheng J, Zhang J, Song G, Y-L Y, Santiago-Morales N, Pei D, Cheng C, Ma J, S-C C, Rusch M, Gupta P, Devidas M, I-M C, Larsen EC, Winick NJ, Carroll WL, Heerema NA, Carroll AJ, M Gastier-Foster JM, Raetz EA, C-H P, Jeha S, Downing JR, Paietta E, Kornblau SM, Marcucci G, Bloomfield C, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG. Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. Blood 122, 2013. e-Pub 2013.
194. Roberts KG, Payne-Turner D, Pei D, Becksfort J, Harvey RC, Li Y Song G, Cheng J, Ma J, Zhang J, Cheng C, S-C C, I-ML C, Devidas M, Larsen EC, Carroll WL, Winick NJ, Heerema NA, Carroll AJ, Gastier-Foster JM, Raetz EA, C-H P, Jeha S, Downing JR, Paietta E, Kornblau SM, Marcucci G, Stock W, Bloomfield CD, Gerhard DS, Loh ML, Hunger SP, Willman CL. Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. Blood 122, 2013. e-Pub 2013.
195. Kornblau SM, Hu CW, Qiu YH, Yoo SY, Zhang N, Ravandi F, Garcia-Manero G, Qutub AA, Coombes KR. Recurrent Patterns Of Histone Methylation and Acetylation Regulating Protein Expression In Acute Myelogenous Leukemia (AML). Blood 122, 2013. e-Pub 2013.
196. Quintas-Cardama A, Post SM, Kojima K, Qiu YH, Andreeff M, Bueso-Ramos CE, Kornblau SM. High p53 Protein Expression LEVEL Independent Of Mutational Status Is An Adverse Prognostic Factor For Survival In ACUTE Myeloid Leukemia. Blood 122, 2013. e-Pub 2013.
197. Kuiper KP, Scheijen B, Pastorczak A, van Reijmersdal SV, Thomas DA, Zhang N, Coombes KR, Kantarjian HM, Jabbour EJ, ESJM DB, van Leeuwen FN, Kornblau SM. Identification of distinct protein Signatures Associated with genetic Abnormalities In Acute Lymphoblastic Leukemia. Blood 122, 2013. e-Pub 2013.
198. Tibes R, Kornblau SM, Pierceall WE, Lena R, Qiu YH, Cardone M, Chaudhuri L, Fauble V, Elashoff M, Blake M, Mesa RA, Bogenberger JM. BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses. Blood 122, 2013. e-Pub 2013.
199. Han L, Zeng Z, Qiu P, Jorgensen JL, Mak DH, Burks JK, McQueen T, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-Cell Mass Cytometry Reveals Phenotypic and Functional Heterogeneity In Acute Myeloid Leukemia At Diagnosis and In Remission. Blood 122, 2013. e-Pub 2013.
200. Hu CW, Qutub AA, Qiu YH, Yoo SY, Zhang N, Pemmaraju N, DiNardo CD, Coombes KR, Kornblau SM. A Global Proteomic Pathway Map In Acute Myeloid Leukemia (AML). Blood 122, 2013. e-Pub 2013.
201. Andreeff M, R-Y W, Davis RE, Jaamo R, Ruvolo P, McQueen T, Huang X, Battula VL, Chen Y, Majumdar S, Benito JM, Zeng Z, Benton C, Carter B, Mu H, Ma W, Ruvolo V, Hodgson L, Konoplev S, Pan R, Somanchi A, Strunck D, Zhang Q, Kornblau SM, Kantarjian H, Marcucci G, Garzon R, Zuber J, Lowe S, Croce C, Konopleva M. Proteomic, gene expression, and micro-RNA analysis of bone marrow mesenchymal stromal cells in acute myeloid leukemia identifies pro-inflammatory, pro-survival signatures in vitro and in vivo. Blood 122, 2013. e-Pub 2013.
202. Kim E, Koehrer S, Rosin NY, Wang Z, Thomas DA, Ravandi F, Kornblau SM, Kantarjian HM, O'Brien S, Estrov Z, Buggy JJ, Muschen M, Davis RE, Burger JA. Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia. Blood 122, 2013. e-Pub 2013.
203. Kornblau SM, Hu CW, Yoo SY, Qiu YH, Zhang N, Borthakur G, Daver NG, Qutub AA, Coombes KR. Classification Of Acute Myelogenous Leukemia (AML) Based On Functionally Related Proteins Groups. Blood 122, 2013. e-Pub 2013.
204. Ruvolo PP, R-Y W, Ruvolo VR, Jacamo R, McQueen T, Borthakur G, Qiu YH, Kevin R Coombes KR, Zhang N, Shpall EJ, Champlin RE, Garzon R, Marcucci G, Croce CM, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. Blood, 2013. e-Pub 2013.
205. Shetty A, Kantarjian HM, Champlin RE, Borthakur G, Badar T, Garcia-Manero G, Andersson BS, Oran B, Ciurea SO, Konopleva M, Andreeff, M, Kornblau SM, Wierda WG, Pierce S, Ravandi F, Cortes JE. Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood 122, 2013. e-Pub 2013.
206. Benito J, Harutyunyan KG, Marzo I, Debose L, Gonzalo O, Zhou P, Jacamo R, Park E, Muschen M, Mulloy J, Bendall L, Zweidler-McKay P, Coombes K, Qiu YH, Zhang N, Leverson J, Thomas DA, O'Brien SM, Kantarjian H, Andreeff M, Kornblau SM, Konopleva M. Acute lymphoblastic leukemia is a Bcl-2 dependent disease: proteomic profiling and pre-clinical efficacy of a selective Bcl-2 antagonist ABT-199. Blood 122, 2013. e-Pub 2013.
207. Kampen KR, Scherpen FJG, Garcia-Manero G, Yang H, Kornblau SM, ESJM DB. EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System. Blood 122, 2013. e-Pub 2013.
208. Cole A, Wang Z, Mattson R, Coyaud E, Hurren R, Gronda M, Lin F, Maclean N, Leung E, Qiu YH, Zhang N, Coombes KR, Minden MD, Houry WA, Hao Z, Kornblau SM, Raught B, Aaron Schimmer A. Targeting The Mitochondrial ClpP As a Novel Therapeutic Strategy For Acute Myeloid Leukemia. Blood 122, 2013. e-Pub 2013.
209. Kornblau SM, Hu CW, Qiu YH, Yoo SY, Zhang N, Kadia TM, Ferrajoli A, Coombes KR, Qutub AA. Hippo Pathway (HP) Activity In Acute Myelogenous Leukemia (AML): Different Prognostic Implications Of TAZ versus YAP Inactivation By Phosphorylation. Blood 122, 2013. e-Pub 2013.
210. Nazha A, Kantarjian HM, Ravandi F, Xuelin H, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brand M, Faderl SH. Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 122, 2013. e-Pub 2013.
211. Rytting ME, Thomas DA, O'Brien S, Schroeder K, Garris R, Cortes JE, Ravandi F, Pemmaraju N, Daver N, Faderl SH, Franklin ARK, Borthakur G, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL). Blood 122, 2013. e-Pub 2013.
212. Joffe E, Coombes KR, Qiu YH, Yoo SY, Zhang N, Bernstam EV, Kornblau SM. Survival Prediction In High Dimensional Datasets – Comparative Evaluation Of Lasso Regularization and Random Survival Forests. Blood, 2013. e-Pub 2013.
213. Gallardo M, Lee HJ, Zhang X, Nazha A, Pageon LR, Kornblau SM, Quintás-Cardama A, Post SM. hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia. Blood 122, 2013. e-Pub 2013.
214. Mahmud H, ter Elst A, Scherpen FJG, Meeuwsen-de Boer TGJ, Kampen KR, Guryev V, de Haas V, Kornblau SM, ESJM DB. Kinomics Profiling Of Pediatric Acute Myeloid Leukemia Based On Prognosis. Blood 122, 2013. e-Pub 2013.
215. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Andreeff M, Carter B. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Molecular Cancer Therapeutics, 2013. PMID: 24337870.
216. Kornblau SM, Jacamo R, McQueen T, Ruvolo V, Qiu YH, Coombes K, Zhang N, Andreeff M, Ruvolo P. Role of Galectin 3 as a regulator of cell survival in Acute Myeloid Leukemia. Blood, 2013. e-Pub 2013.
217. Pierceall WE, Carlson N, Richard D, Huang X, Elaschoff M, Konopleva M, Kornblau SM, Cardone M, Andreeff M. BH3 Profiling is a Predictive Biomarker for Response to Cytarabine-based Treatment of Acute Myelogenous Leukemia. ASCO 2013, 2013. e-Pub 2013.
218. Konopleva M, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Ruvolo P, Huang X, Kadia T, Feliu J, Burger J, Andreeff M, Kornblau SM, Estey E, Kantarjian. Phase II study of the oral AKT inhibitor, MK-2206, for acute myeloid leukemia (AML) in 2nd relapse. AACR 2013, 2013. e-Pub 2013.
219. Kornblau SM, Qutub A, Yao H, York H, Qiu Y, Graber D, Andreeff M, Zhang N, Coombes KR. Protein Expression in Acute Myelogenous Leukemia CD34+CD38- Stem Cells is Markedly Different from CD34+ and Bulk Leukemic Cells. Blood, 2013. e-Pub 2013.
220. Tibes R, Kornblau SM, Pierceall WE, Lena R, Fauble V, Slack J, Leis J, Valdez R, Cardone M, Dueck A, Bogenberger JM. BH3 Profiling as Predictive Biomarker for Hypomethylating Agent Response. Leukemia Research 122(21), 2013.
221. Ruvolo PP, Jacamo R, McQueen T, Pan R, Samudio I, Konopleva M, Kornblau SM, Garzon R, Croce C, Andreeff M. Suppression of miR-93 May Regulate Anti-Oxidant Metabolism in Mesenchymal Stromal Cells Derived from Acute Myeloid Leukemia Patients. Blood, 2013. e-Pub 2013.
222. Kornblau SM, Pierce A, Meyer S, Ravandi F, Borthakur G, Coombes KR, Zhang N, Whetton A. Transglutaminase2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility. Blood 120, 2012. e-Pub 2012.
223. Kojima K, Kornblau SM, Ruvolo V, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu Y, Burks JK, Ruvolo P, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 120, 2012. e-Pub 2012.
224. Madan V, W-W C, Wen DL, Garg M, Hattori N, Qiaoyang S, Yang H, NagatoaY, Yoshida K, Sanada M, Okuno Y, Alpermann T, Chendamarai E, Ganesan S, Nowak D, Nakamaki T, Kawamata N, Ikezoe T, Kham KY, Matthews J, Lizhen L, Xuan M, Lin LS, Blau O, Kornblau SM, Andreeff M, Tomoyasu S, W-K H, Yeoh A, Ogawa S, Mathews V, Haferlach T, L-Y S, Koeffler P. Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes. Blood 120, 2012. e-Pub 2012.
225. Tabe Y, Jin L, Hatanaka Y, Miida T, Kornblau SM, Andreeff M, Konopleva M. TGF-β1 supports leukemia cell survival via negative regulation of FLI-1 transcription factor, ERK inactivation and MMP-1 secretion. Blood 120, 2012. e-Pub 2012.
226. Carter BZ, Mak PY, Chen Y, Jacoma R, Ruvolo V, Mak DH, McQueen T, Konopleva M, Kornblau SM, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain (ARC) Increases AML Cell Migration and Adhesion in vitro and in vivo by Regulating Leukemia-Stroma Interactions. Blood 120, 2012. e-Pub 2012.
227. Ruvolo PP, Jacamo R, Ruvolo VR, Ruvolo MA, Burks JK, Battula VL, McQueen T, Konopleva M, Kornblau SM, Garzon R, Croce C, Andreeff M. Exosomes mediate communication between the microenvironment and leukemic cells in Acute Myeloid Leukemia. Blood 120, 2012. e-Pub 2012.
228. Chae YK, Zhang N, Qiu Y, Kadia TM, Ferrajoli A, Coombes KR, Kornblau SM. Proteomic Profiling of Smad Proteins expression in AML: Pan Expression with High Phosphorylation is Prognostically Adverse. Blood 120, 2012. e-Pub 2012.
229. R-Y W, Qiu Y, Yoo SY, McQueen T, Chen Y, Zeng Z, Coombes KR, Schober W, Konopleva M, Kornblau SM, Andreeff M. Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences from Normal MSC. Blood 120, 2012. e-Pub 2012.
230. Carter BZ, Mak PY, Mak DH, Ruvolo V, Jacoma R, Kornblau SM, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML. Blood 120, 2012. e-Pub 2012.
231. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Kornblau SM, McQueen T, Weng D, Burns J, Andreeff M. Antagonizing IAPs by SMAC Mimetic Birinapant Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy in vitro and in vivo. Hematologic Malignancies 2012, 2012. e-Pub 2012.
232. Kojima K, Kornblau SM, Ruvolo V, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Ruvolo P, Shacham S, Kauffman M, Andreeff. Prognostic Impact and Targeting of CRM1 in Acute Myeloid Leukemia. Hematologic Malignancies 2012, 2012. e-Pub 2012.
233. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garris R, Cortes JE, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab). Blood 118(21):661-62, 2011. e-Pub 2011.
234. Shoukier M, Kantarjian HM, Jabbour E, Quintas-Cardama A, Estrov Z, Kadia T, Borthakur G, Garcia-Manero G, Kornblau SM, Burton EM, O'Brien S, Cortes JE. Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML). Blood 118, 2011. e-Pub 2011.
235. Quintas-Cardama A, Qiu Y, Post S, Kornblau SM. High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia. Blood 118(21):646-47, 2011. e-Pub 2011.
236. Shoukier M, Kantarjian HM, Jabbour E, Quintas-Cardama A, Estrov Z, Kadia T, Borthakur G, Garcia-Manero G, Kornblau SM, Burnton EM, O'Brien S, Cortes JE. Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts). Blood 118(21):1189, 2011. e-Pub 2011.
237. Carter BZ, Mak DH, Qiu Y, Kornblau SM, Mak PY, Weng D, McKinlay MA, Andreeff. Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy. Blood 118(21):32, 2011. e-Pub 2011.
238. Bogengerger JM, C-X S, Gonzales I, Tiedemann RE, Noel P, Slack JL, Mesa RA, Stewart K, Qiu Y, Coombes KR, Kornblau SM, Azorsa D, Tibes R. RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells. Blood 118(21):1498, 2011. e-Pub 2011.
239. Borthakur G, Andreeff M, Coombes KR, Qiu Y, Duvvuri S, Zhang N, Ruvolo V, Konopleva M, Garcia-Manero G, Ruvolo PP, Cortes JE, Kantarjian HM, Kornblau SM. High expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukema- Time to Target Autophagy to Improve Therapy Outcomes?. Blood 118(21):1076-77, 2011. e-Pub 2011.
240. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes JE, Kantarjian HM, Andreeff M, Kornblau SM. Survivin Is Highly Expressed in AML Stem Cells and Predicts Poor Clinical Outcome. Blood 118(21):108-9, 2011. e-Pub 2011.
241. Elst A, Kampen KR, Diks SH, Kornblau SM, Garcia-Manero G, De Bont ES. EphrinB1 Activation As a Potential New Treatment Option in AML. Blood 118, 2011. e-Pub 2011.
242. Qintas-Cardama A, Qiu Y, Post S, Kornblau SM. Low Expression of the Novel Tumor Suppressor Trim62 Is An Independent Adverse Prognostic Factor for Survival In Acute Myeloid. Blood 118(21):259, 2011. e-Pub 2011.
243. Quintas-Cardama A, Qiu Y, Post S, Zhang Y, Creighton C, Cortes JE, Kornblau SM. Proteomic Profiling of 112 Proteins in Chronic Myeloid Leukemia Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Distinct Protein Expression Signatures Associated with Advanced Phase Disease and the CD34+ Compartment. Blood 118(21):1071, 2011. e-Pub 2011.
244. Gruber TA, Gedman AL, Ta HQ, Zhang J, Koss C, S-C C, Su X, Gupta V, Ogden S, Andersson AK, Easton J, Wang J, Rusch M, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian HM, Nimer SD, Doehner K, Doehner H, Ley TJ, Shurtleff S, Rubnitz J, C-H P, Mardis ER, Wilson RK, Downing JR. Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood 118(21):344, 2011. e-Pub 2011.
245. Cohen AC, Y-W H, Cesano A, Hawtin RE, Ware JR, Arulrajah B, Kornblau SM. Single Cell Network Profiling (SCNP) Reveals Age-and Disease-Based Heterogeneity in Healthy Individuals and in Patients with Low Risk (LR) Myelodysplastic Syndrome (MDS). Blood 118(21):1201, 2011. e-Pub 2011.
246. Shih AY, Schairer A, Barrett CL, Geron I, Court Recart AC, Goff D, Prashad S, Wi J, Jiang Q, Gotlib J, Balaian L, Minden MD, Leu H, Wall R, Ma W, Shazand K, McPherson JD, Kornblau SM, Deichaite I, Pu M, Bao L, Martinelli G, Reya T, Morris SR, VanArsdale T, Hudson TJ, Messer K, Mikkola H, Levin WJ, Frazer KA, Sadarangani A, Jamieson C. Cycling Toward Leukemia Stem Cell Elimination With a Selective Sonic Hedgehog Antagonist. Blood 118(21):1613, 2011. e-Pub 2011.
247. Ruvolo PP, Ruvolo V, Zeng Z, Qui Y, Zhou L, Gallagher KE, Konopleva M, Kornblau SM, Andreeff M. The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells. Blood 118(21):182, 2011. e-Pub 2011.
248. Nazha A, Ravandi F, Kantarjian HM, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brant M, Faderl S. Clofarabine, Idarubicin, and Cytarabin (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 118(21):674, 2011. e-Pub 2011.
249. Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. NPM1 mutation occurs in a subset of Ph+ AML suggesting that this entity is distinct from CML in myeloid blast phase. AMP, 2011. e-Pub 2011.
250. Estecio MR, Jelinek J, Garber D, Lu Y, Ramagli L, Liang S, Kornblau SM, J-P I. Genome-Wide Epigenetic Analysis of Cancer Stem Cells (CSCs) In Acute Myeloid Leukemia. Blood 116(21):1497, 2010. e-Pub 2010.
251. King C, Sellers S, Krouse AE, Metzger ME, Traversari C, Bordignon C, Kornblau SM, Marini F, Donahue RE, Dunbar CE. Suicide Gene (HSVtk) Ablation of Hematopoietic Stem Cells and Teir Progeny In the Rhesus Macaque Model: An Approach to Deletion of Dangerous Clones. Blood 116(21):1540, 2010. e-Pub 2010.
252. Coombes KR, Zhang N, Ruvolo V, Konopleva M, Andreeff M, Kornblau SM. Role for PP2A Regulatory Subunit B55a as A Regulator of AKT and Other Signaling Pathways in AML. Blood 116(21):699-700, 2010. e-Pub 2010.
253. Shi X, Szymanska B, Carol H, Bohem I, Lu H, Konoplev S, Fang W, Kornblau SM, Zweidler-McKay P, Wilson W, Campana D, Borthakur G, Bueso-Ramos CE. Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104. Blood 116(21):379-380, 2010. e-Pub 2010.
254. Kornblau SM, Y-H Q, Zhang N, Coombes KR, O'Brian S, Kantarjian HM, Thomas DA. Proteomic Profiling of 128 Proteins In 194 Acute Lymphocytic Leukemia (ALL) Patients Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. Blood 116(21):1325, 2010. e-Pub 2010.
255. Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Liu JS, Kornblau SM, Grable M, I-R H, Borthakur G, Mankin A, Bivins C, Garcia-Manero G. Phase I Trial Results for SL-4021, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-jTreated AML, Poor Risk Elderly AML, and High Risk MDS. Blood 116(21):1351, 2010. e-Pub 2010.
256. Kornblau SM, Y-H Q, Zhang N, Coombes KR, Graber D, Garcia-Manera G, Kantarjian HM. Proteomic Profiling In CD34+CD38- Stem Cells and CD34+ Cells From 185 Myelodysplasia Patients Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurretn Proteins Expression Signatures with Prognostic Implications. Blood 116(21):879, 2010. e-Pub 2010.
257. Ravandi F, Patel KP, Luthra, Faderl S, Monopleva M, Kadia T, Brandt M, Pierce S, Kornblau SM, Garcia-Manero G, Cortes JE, Kantarjian H. Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. Blood 116(21):1115-1116, 2010. e-Pub 2010.
258. Wierda G, Garcia-Manero G, Verstovsek S, Konopleva M, Kadia T, Kornblau SM, Fayad L, Romaguera J, Cortes JE, Kantarjian H. Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants. Blood 116(21):1167-1168, 2010. e-Pub 2010.
259. Zeng Z, Shi Y, Tsao T, Qiu Y, Kornblau SM, Baggerly K, Liu W, Liu Y, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting mTORC1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment. Blood 116(21):341-342, 2010. e-Pub 2010.
260. Kornblau SM, Scherpen F, Y-H Q, Zhang N, Coombes KR, De Bont ES. Epidermal Growth Factor Receptor Expression and activity In Acute Myeloid Leukemia. Blood 116(21):1294-1295, 2010. e-Pub 2010.
261. Kornblau SM, Y-H Q, Zhang N, Coombes KR, Watson DK. Abnormal Expression of Friend Leukemia Virus Integration 1 (Fli1) Protein Is An Adverse Prognostic Factor In AML. Blood 116(21):702, 2010. e-Pub 2010.
262. Kornblau SM, Huo Y, Brandt M, Zhang N, iu H, Ravandi F, Kadia T, Pierce S. Effect of FLT3 and RAS Mutations on Protein Expression Patterns In Cases of Acute Myelogenous Leukemia (AML) with NPM1 Mutations. Blood 116(21):1115, 2010. e-Pub 2010.
263. Minden MD, Kornblau SM, Rosen DB, Cohen AC, Gayko U, Putta S, Woronicz J, Fantl WJ, Alessandra Cesano A. FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations. Blood 114(22):635, 2009. e-Pub 2009.
264. Lee DW, Bueso-Ramos CE, Carroll M, Whichard Z, Feng Y, Stein P, Jensen SA, Kornblau SM, Corey SJ. SHIP1 Is a Novel Tumor Suppressor in Late-Stage Myelodysplastic Syndromes and Is Silenced by Mir-210 and Mir-155. Blood 114(22):1471, 2009. e-Pub 2009.
265. Konopleva M, Benito J, Y-X S, Konoplev S, Kornblau SM, Frolova O, Zweidler-McKay PA, Qiu Y, Wilson WR, Campana D, Jacamo R, Lu H, Fang W, Borthakur G, Bueso-Ramos CE, Kantarjian HM, Thomas DA, Andreeff M. Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia. Blood 114(22):805, 2009. e-Pub 2009.
266. Taby RF, Yellapragada SV, Kroeger H, He R, Kornblau SM, Kantarjian H, Farhad Ravandi F, Jelinek J, J-P I. Validation of a DNA Methylation Signature of Favorable Prognosis in Newly Diagnosed Acute Myeloid Leukemia. Blood 114(22):645, 2009. e-Pub 2009.
267. Ayoubi M, Thomas DA, Kantarjian H, O'Brien S, Ravandi F, Garcia-Manero G, Verstovsek S, Rytting M, Borthakur G, Kadia T, Kornblau SM, Andreeff M, Feliu J, Faderl S. Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase. Blood 114(22):802, 2009. e-Pub 2009.
268. Cesano A, Woronicz J, Cohen AC, Covey T, Putta S, Gayko U, Fantl WJ, Kornblau SM. Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure. Blood 114(22):165, 2009. e-Pub 2009.
269. Kadia T, Kornblau SM, Kantarjian H, Faderl S, Jones D, Garcia-Manero G, Borthakur G, Koller C, Verstovsek S, Pierce S, Cortes J, Ravandi F. Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia. Blood 114(22):139, 2009. e-Pub 2009.
270. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau SM, Andreeff M, Garris R, Keating MJ, O'Brien S. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 114(22):344, 2009. e-Pub 2009.
271. Carter BZ, Zhang N, Coombes KR, Mak DH, Qiu Y, Thomas DA, Ravandi F, Kantarjian H, Andreeff M, Kornblau SM. Expression of Apoptosis Repressor with Caspase Recruitment Domain (ARC), An Antiapoptotic Protein, Is Strongly Prognostic in Acute Myeloid Leukemia (AML). Blood 114(22):166, 2009. e-Pub 2009.
272. Pemmaraju N, Kantarjian HM, Ravandi F, Garcia-Manero G, Gautam B, Parikh SA, Konopleva M, Kornblau SM, Andreeff M, O'Brien S, Cortes J. FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status. Blood 114(22):424, 2009. e-Pub 2009.
273. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen AC, Covey T, Fantl WJ, Gayko U, Alessandra Cesano A. Single Cell Network Profiles in Non-M3 AML Associated with Patient Response to Standard Induction Therapy. Blood 114(22):633, 2009. e-Pub 2009.
274. Kornblau SM, Singh N, Qiu Y, Chen W, Faderl S, Borthakur G, Konopleva M, Zhang N, Coombes K. Highly Phosphorylated FOXO3A Is An Adverse Prognostic Factor in Acute Myeloid Leukemia. Blood 114(22):166, 2009. e-Pub 2009.
275. Ferrajoli A, OBrien S, Wierda W, Faderl S, Kornblau SM, Yerrow K, Estrov Z, Kantarjian H, Keating M. Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood 112(11):23, 2008. e-Pub 2008.
276. Kornblau SM, Qiu Y, Chen W, Chou P, Blau L, Nashino H, Ravandi F, Andreeff M, Kantarjian H, Neeley S, Ju Z, Zhang N, Coombes KR. Proteomic Profiling of 150 Proteins in 511 Acute Myelogenous Leukemia (AML) Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. Blood 112(11):281-282, 2008. e-Pub 2008.
277. Kornblau SM, Qiu YH, Graber D, Chen W, Melendez J, Konopleva M, Faderl S, Andreeff M, Borthakur G, Yao H, Coombes KR. Protein Expression in Acute Myelogenous Leukemia Stem Cells Compared to Bulk AML Cells Using Reverse Phase Proteins Arrays (RPPA). Blood 112(11):881, 2008. e-Pub 2008.
278. Konoplev S, Kornblau SM, Schlette E, Lu H, Thomas DA, Zhang N, Qiu YH, Coombes K, Neeley S, Kantarjian H, Medeiros LJ, Andreeff M, Konopleva M. Overexpression of HIF1 Alpha Predicts Worse Overall and Event-Free Survival in Patients with Philadelphia Chromosome-Negative Precursor B-Lymphoblastic Leukemia. Blood 112(11):870, 2008. e-Pub 2008.
279. Andreeff M, McQueen T, Williams C, Gu J, Hopwood VL, Appleberry T, Rich C, Dallaire S, Kornblau SM, R-Y W. Clonal Abnormalities in MSC Derived from AML Bone Marrows. Blood 112(11):845-846, 2008. e-Pub 2008.
280. Jovanovic JV, Guidez F, Ravandi F, Duprez E, Patel M, Mills K, Kornblau SM, Aldouri M, Auger M, Burnett AK, Solomon E, Grimwade D. Defining the Landscape of Resistance Mutations in the Context of Modern Treatment Protocols for Acute Promyelocytic Leukemia (APL). Blood 112(11):530-531, 2008. e-Pub 2008.
281. Tong W, Kantarjian H, O’Brien S, Faderl S, Ravandi F, Wierda WG, Kornblau SM, Borthakur B, Garcia-Manero G, Burton E, Rios MB, Cortes J. Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction. Blood 112(11):741, 2008. e-Pub 2008.
282. Santos FPS, Kantarjian H, Fava C, OBrien S, Garcia-Manero G, Kornblau SM, Ravandi F, Wierda W, Cortes J. Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML). Blood 112(11):1104, 2008. e-Pub 2008.
283. Jelinek J, Kroeger H, He R, Saraf A, Lau SM, T-V N, Thomas MW, Shpall EJ, Kornblau SM, Bueso-Ramos C, Kantarjian HM, Issa JP. Hypermethylation of HOX Genes Is Associated with Longer Survival in Acute Myeloid Leukemia. Blood 112(11):121, 2008. e-Pub 2008.
284. Faderl S, Thomas SA, Ravandi F, Garcia-Manero G, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau SM, OBrien S, Vu K, Kwari M, Bretz J, Kantarjian HM. Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone(Augmented Hyper-CVAD) Has Activity in Adult Patients with Relapsed/Refactory Acute Lymphoblastic Leukemia (ALL). Blood 110(11):149B, 2007. e-Pub 2007.
285. Andersson BS, Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau SM. Anti-Apoptotic Proteins, HSP90 and Activated STAT3 Contribute to Busulfan Resistance of Myeloid Leukemia Cells,. Blood 110(11):1017a, 2007. e-Pub 2007.
286. Kornblau SM, Barnett J, Qiu Y, Chen W, Faderl S, Coombes KR, Andreeff M. P53 Protein Expression Levels Are Prognostic in AML and Predict for Mutational Status. Blood 110(11):708a, 2007. e-Pub 2007.
287. Wang R, Samudio IJ, McQueen T, Schober WD, Ruvolo VR, Kornblau SM, Konopleva M, Andreeff. Apoptosis Inducing Factor Acts as a Suvival Factor in Acute Myelogenous Leukemia through Mitochondrial Complex 1. Blood 110(11):537a, 2007. e-Pub 2007.
288. Kornblau SM, Qiu Y, Chen W, Verstovsek S, Coombes KR, Mills GB. Protein Expression Signatures Determined by Reverse Phase Proteins Arrays (RPPA) Accurately Predict FLT3-ITD Mutation Status in AML. Blood 110(11):708a, 2007. e-Pub 2007.
289. Tibes R, Meurice N, Anthony SP, Qiu Y, Kornblau SM, Mousses S, Petit J. Mathematical Models To Identify Combined Protein and Clinical Biomarkers of Response to Induction Chemotherapy in acute Myeloid Leukemia (AML). Blood 110(11):788a, 2007. e-Pub 2007.
290. Kornblau SM, Qiu Y, Palla SL, Zhihong Z, Chen W, Borthakur G, Coombes KR, Konopleva M. Patterns and Prognostic Impact of P13K-AKT Pathway Activation, Regulation and Downstream Activity in AML Using Reverse Phase Proteins Arrays (RPPA). Blood 110(11):706a, 2007. e-Pub 2007.
291. Kornblau SM, Qiu Y, Chen W, Liang H, Ravandi F, Coombes KR, Nagarajan L. Expression and Prognostic Impact of Candidate Suppressor Sequence-Specific Single-Stranded DNA Binding Protein (SSBP2) in AML Using Reverse Phase Proteins Arrays (RPPA). Blood 110(11):707a, 2007. e-Pub 2007.
292. Verstovsek S, Tefferi A, Kornblau SM, Thomas D, Cortes J, Ravandi-Kashani F, Garcia-Manero G, Kantarjian H. Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 110(11):1037a, 2007. e-Pub 2007.
293. Jabbour E, Kanarjian H, Shan J, O'Brien S, Wierda W, Ravandi F, Borthakur G, Kornblau SM, Walker BK, Rios MB, Cortes J. Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs). Blood 110(11):577a, 2007. e-Pub 2007.
294. Jabbour E, Kantarjian H, Atallah E, Borthakur G, Wierda W, Faderl S, Kornblau SM, Cortes J. Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML). Blood 110(11):313a, 2007. e-Pub 2007.
295. Andersson BS, Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau SM. Anti-Apoptotic Proteins, HSP90 and Activated STAT3 Contribute to Busulfan Resistance of Myeloid Leukemia Cells. Blood 110(121):1017a, 2007. e-Pub 2007.
296. Alvarado Y, Kantarjian H, Freireich EJ, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau SM, Laddie N, Smith L, Cortes J. Phase II dosing study of cytarabine chemotherapy in combination with cenesen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). Journal of Clinical Oncology 2007 ASCO Annual Meeting 25(18S):364s, 2007. e-Pub 2007.
297. Kornblau SM, Qiu Y, Tibe R, Chen W, Lemker E, Andreeff M, Coombes KR, Mills GB. High Throughput Proteomic Analysis of 559 Acute Myelogenous Leukemia (AML) Patient Samples on a Single Slide Using Reverse Phase Proteins Arrays (RPPA): Analysis of Signal Transduction Pathway (STP) and Apoptosis Regulating Proteins. Blood 108(11):36a, 2006. e-Pub 2006.
298. Giles F, Bergstrom A, Garcia-Manero G, Kornblau S, Andreeff M, Kantarjian H, Jones D, Freedman SJ, Verstovsek S. MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2 Positive Myeloproliferative Disease (MPD). Blood 108(11):309b-310b, 2006. e-Pub 2006.
299. Giles F, Freedman SJ, Xiao A, Borthakur G, Garcia-Manero G, Wierda W, Kornblau SM, O'Brien S, Bergstrom DA, Rizzieri DA. A Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphi-Positive ALL. Blood 108(11):556a, 2006. e-Pub 2006.
300. Faderl S, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Wierda WG, Borthadur G, Thomas D, Cortes J, Kornblau SM, Estrov Z, Andreeff M, Beran M, Giles F, Huang X, Kwari M, Kantarjian HM. Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage. Blood 108(11):51a, 2006. e-Pub 2006.
301. R-Y W, Ruvolo VR, McQueen T, Schober WD, Kornblau SM, Konopleva M, Andreeff M. Overexpression of Apoptosis-Inducing Factor (AIF) and Pro-Survival Function in AML. Blood 108(11):176b-177b, 2006. e-Pub 2006.
302. Kornblau SM, Milella M, Ball G, Qiu YH, Patel S, Ruvolo PP, Estrov Z, Beran M, Kantarjian HM, May WS, Andreeff M. ERK2 and phospho-erk2 are prognostic for survival in AML and complement the prognostic impact of BAX and BCL2. Blood 108:2358-2365, 2006. e-Pub 2006.
303. Tibes R, Qiu Y, Coombes K, Hennessy B, Kantarjian H, Giles F, Estey E, Mills G, Kornblau SM. Proteomic signatures of acute myeloid leukemia (AML) distinguishes different outcome groups across cytogenetics and identified potential therapy targets. Clinical Oncology 24(18S), 2006. e-Pub 2006.
304. Quintas-Cadama A, Kantarjian H, Garcia-Manero, Thomas D, Kornblau SM, Estey E, Nemri M, Cortes J, Giles F, Verstovsek S. A Phase II Study of Azacitidine (Vidaza) for Patients with Myelofibrosis (MF). Blood 108(11):289, 2006. e-Pub 2006.
305. Giles F, Freedman SJ, Xiao A, Borthakur G, Garcia-Manero G, Wierda W, Kornblau SM, O'Brien S, Bergstrom DA, Rizzieri DA. MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphi-Positive ALL. Blood 108:11:556a, 2006. e-Pub 2006.
306. Thomas DA, Kantarjian HM, Lorgensen JL, Faderl S, Cortes J, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Koller CA, Beran M, Kornblau SM, Andreeff M, Jones D, O'Brien S. Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Blood 108(11):527a, 2006. e-Pub 2006.
307. Kornblau SM, McCue D, Ku LK, Chen W, Coombes KR. Cytokine Profiling of Acute Meylogenous Leukemia and Myelodysplasia. Blood 108(11):667a, 2006. e-Pub 2006.
308. Sun X, Wang E, Jones DM, Shen H, Johnson, Issa MM, J-P I, Amin H, Ginsberg CF, Kantarjian HM, Andreeff M, Kornblau SM, Glassman AB, Arlinghaus RB, Center MD, Houston, TX, Genetics L, Woodland T, TX. SOX4 gene expression in human leukemic and benign hematopoietic cells. AACR 97th Annual Meeting 2006 47, 2006. e-Pub 2006.
309. Berenson JR, Boccia RV, Hussein MA, Belch A, Boise L, Schwartz B, Gale RP, Kornblau SM. Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM). Blood 108(11):556a, 2006. e-Pub 2006.
310. Tibes R, Lu YL, Giles F, et al. Reverse phase protein array (RPPA): Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens. Clin Cancer Res 11(24):9163S-9164S, 2005. e-Pub 2005.
311. Kornblau SM, Banker DE, Lemker E, Estrov Z, Faderl S, Verstovsek S, Cortes J, Garcia-Manero G, Koller C, Ravandi-Kashani F, Andreeff M, Jackson CE, Chen W, Petersdorf S, Estey E, Appelbaum F. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to Idarubicin plus high dose Ara-C: A phase I study. Blood 106(11):122A-122A, 2005. e-Pub 2005.
312. Kornblau SM, Qiu YH, Tibes R, Lu Y, Mills GB. Time course proteomic profiling of signal transduction and apoptosis pathways in AML survivor cells using reverse phase protein lysate microarray (RPPA) reveals differential effect of time, dose and agents(s). Blood 106(11):355A-355A Part 1, 2005. e-Pub 2005.
313. Lima D, M, Giralt, S, Caldera, Z, et al. Results of a phase I/II study of gemtuzumab ozogamicin added to fludarabine (F), melphalan (M) and allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed myeloid leukemias. Blood 106(11):248a, 2005. e-Pub 2005.
314. Lee DW, Q-S Z, Rudra S, Shpall EJ, Kornblau SM, Corey SJ. Abnormal PI 3-Kinase Activity Due to Increased Lyn with Decreased PTEN and Absent SHIP in Bone Marrow Cells from Patients with Myelodysplastic Syndromes. Blood 106, 2005. e-Pub 2005.
315. Konopleva M, Samudio I, Tsao T, Konblau SM, Y-X S, McQueen T, Contractor R, Sporn MB, Meyer CJ, Huff W, Safe SH, Kantarjian H, Andreeff M. Mechanisms and Activity of PPAR/ Active Triterpenoids CDDO and CDDO-Me in Leukemias. Blood, 2005. e-Pub 2005.
316. Drabkin HA, Puvolo V, Gadgil S, Chen W, Zeng C, Baron AE, Kornblau SM, Estey E, Coombes KR, Andreeff M. Comprehensive HOX Gene Expression Profiles Are Associated with Major Cytogenetic Prognostic Categories in AML. Blood, 2005. e-Pub 2005.
317. Tibes R, Qiu YH, Coombes KR, Gold D, Mills GB, Kornblau SM. Classification of acute myelogenous leukemia (AML) based on patterns of signal transduction pathway (STP) and apoptosis regulating protein activation determined by reverse phase proteins arrays (RPPA). Blood 106(11):145A-145A, 2005. e-Pub 2005.
318. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles F, Garcia-Manero G, Kornblau SM, Andreeff M, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 106(11):520A-521A, 2005. e-Pub 2005.
319. Thomas DA, Cortes J, O'Brien S, Faderl S, Ravandi F, Garcia-Manero G, Giles F, Beran M, Koller C, Wierda W, Verstovsek S, Ferrajoli A, Kornblau SM, Keating M, Andreeff M, Kantarjian H. Update of the modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 106(11):521A-521A, 2005. e-Pub 2005.
320. Faderl S, Thomas DA, Garcia-Manero G, Ravandi F, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau SM, Vu K Jarmon R, Kantarjian HM. Augmented Hyper-CVAD in acute lymphoblastic leukemia (ALL): The MDACC experience with intensified L-asparaginase and vincristine in adult ALL salvage. Blood 106(11):523A-523A, 2005. e-Pub 2005.
321. Lee SY, Chen JJ, Zhou GL, Shi R, Kocherginsky M, Karrison TG, Kim YC, Ge X, Jayathilaka N, Neilly MB, Bouffard G, Young A, Kornblau SM, Bloomfield C, Bohlander S, Liu PP, Sun M, Wang SM, Rowly JD. Gene expression profiles in acute myeloid leukemia (AML): From diagnosis to prognosis. Blood 106(11):839A-840A, 2005. e-Pub 2005.
322. de Lima M, Couriel D, Munsell M, Westmoreland M, Shah H, deJesus J, Hosing C, Ghosh S, Anderlini P, Gajewski J, Andersson B, Kornblau S, Hocking B, Ippoliti C, Giralt S, Shpall E, Champlin R. Pentostatin, Tacrolimus, and Mini-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study. Blood 104:208a, 2004. e-Pub 2004.
323. Thomas DA, Faderal S, Cortes J, O'Brien S, Giles F, Garcia-Manero G, Kornblau S, Andreeff M, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood 104:748a, 2004. e-Pub 2004.
324. Lee DW, Zhu Q, Zamore G, Nwawka O, Shpall EJ, Kornblau SM, Corey SJ. Distrubed Regulation and Activity of PI 3-Kinase Activity Due to Enhanced Lyn Kinase but Decreased Ship-1 and Gab2 Levels in Patients with Myelodysplastic Syndrome. Blood 104:933a, 2004. e-Pub 2004.
325. Beran M, Verstovsek S, Kornblau SM, Estey EH, Giles F, Garcia-Manero G, Kantarjian HM. Prolonged Administration of Arsenic Trioxide (Trisenox) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study. Blood 104:266b, 2004. e-Pub 2004.
326. Faderl S, Ferrajolil A, Wierda W, Verstovek S, Ravandi-Kashani F, Garcia-Manero G, Estey E, Thomas DA, Kornblau S, Kwari M, Gandhi V, Kantarjian HM. Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relasped and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML). Blood 104:501a, 2004. e-Pub 2004.
327. Kojima K, Konopleva M, Shikami M, Cabreira-Hansen M, Jackson CE, Shpall EJ, Kornblau SM, Vassilev LT, Andreeff M. Inhibition of p53-MDM2 Interaction by Small-Molecule Antagonist of MDM2 Effectively Induces Apoptosis in Leukemias. Blood 104:695a, 2004. e-Pub 2004.
328. Kornblau S, Qui YH, Cade JS, Lemker EM, Giles F. Survivor Cells Predict Which Patients Will Respond to Therapy with VNP4010M and Ara-C. Blood 104:559a, 2004. e-Pub 2004.
329. Berman J, Heinrichs S, Ortiz TM, Kornblau SM, Neuberg DS, Estey EH. Look AT: CD34+ Cell Selection Is Required to Accurately Measure HOXA9 Levels by Quantitative RT-PCR in Patients with Myelodysplastic Syndrome. Blood 104:266b, 2004. e-Pub 2004.
330. Kornblau SM, Womble M, Jackson CE, Chen W, Estey E, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 104:818a, 2004. e-Pub 2004.
331. Thomas DA, Garcia-Manero G, Cortes J, O'Brien S, Jeha S, Andreeff M, Kornblau SM, Letvak L, Talpaz M, Kantarjian HM. Results of intensive chemotherapy with hyper-CVAD and Imatinib mesylate in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Proc. American Society Clinical Oncology 22:588, 2003. e-Pub 2003.
332. Wierda W, O'Brien S, Ferrajoli A, Faderl S, Kornblau SM, Andreeff M, Koller C, Garcia-Manero G, Thomas D, Kantarjian H. Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL. Blood 102:360b, 2003. e-Pub 2003.
333. Andreeff M, Tabe Y, Milella M, Carter B, Tsao T, McQueen T, Chism D, Schober W, Hu W, Hu G, Marini F, Kitada S, Schimmer A, Kornblau SM, Konopleva M, Reed J. The Role of Apoptosis and Cell Signaling in Myeloid Leukemia. Japanese Cytometry Society Meeting. Cytometry Research 102:880a, 2003. e-Pub 2003.
334. Kornblau SM, Womble M, Cade J, Qiu YH. Does protein expression in AML blasts differ depending on whether they are from the peripheral blood or bone marrow?. Blood 102:193b, 2003. e-Pub 2003.
335. Milella M, Konopleva M, Tabe Y, Precupanul C, Gregorj C, Carter BZ, Kornblau SM, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoic acid (RA) into extensive apoptosis. Blood 102:595a, 2003. e-Pub 2003.
336. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Garcia-Manero G, Keating M, Kornblau S, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Update of the hyper-CVAD and Imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL. Blood 102:225a, 2003. e-Pub 2003.
337. Kornblau SM, Qiu YH, Zhou X, Bekele BN, Cade JS, Jackson CE. Patterns of expression of apoptosis regulating proteins in survivor cells from AML patients predict response to therapy and survival. Blood 102:223b, 2003. e-Pub 2003.
338. Giles F, Kantarjian H, Cortes J, Tsimberidou A, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Andreeff M, O'Brien S, Beran M, Estey E. Adaptive randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes. Blood 102:253b, 2003. e-Pub 2003.
339. Thomas DA, Cortes J, Giles F, O'Brien S, Faderl S, Garcia-Manero G, Beran M, Koller C, Andreeff M, Kornblau S, Keating M, Kantarjian H. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 102:3274, 2003. e-Pub 2003.
340. M-C G, Qiu J, Kornblau SM, Andreeff M, Margolin JF. Identification of low- and high-risk markers in acute lymphoblastic leukemia. Blood 102:577a, 2003. e-Pub 2003.
341. Kornblau, SM, Aycox P, Marini FC. Control of GVHD with maintenance of the GVL effect using retrovirally transduced suicidal lymphocytes in a murine model. Blood 102:700a, 2003. e-Pub 2003.
342. Frolova O, Konopleva M, Ricciardi M, Andreeff M, Kornblau SM. Development of an in vivo murine model to evaluate the efficacy of small molecule inhibitors for the treatment of leukemic cells with activated MAPK/ERK signaling. Blood 102:195b, 2003. e-Pub 2003.
343. Taylor ML, Kornblau SM. Simultaneous measurement of multiple signal transduction pathways in AML patients at diagnosis and relapse. Blood 102:227b, 2003. e-Pub 2003.
344. Thomas DA, Wierda W, Faderl S, O'Brien S, Kornblau S, Koller C, Bantia S, Kiltpatrick JM, Bennett JC, Kantarjian H, Gandhi V. Preliminary activity of intravenous BCX-1777 in aggressive T-cell malignancies. Blood 102:261b, 2003. e-Pub 2003.
345. Thomas DA, Cortes J, Giles F, O'Brien S, Faderl S, Garcia-Manero G, Beran M, Koller C, Andreeff M, Kornblau S, Keating M, Kantarjian H. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 100:329a, 2002. e-Pub 2002.
346. Kornblau S, Qui YH, Womble MF, Cade JS, Jackson CE, Milella M, Konopleva M, Andreeff M. Effect of MEK inhibition with PD184352 Ara-C on patterns of expression of apoptosis regulating proteins in acute myelogenous leukemia (AML) survivor cells. Blood 11:732a, 2002. e-Pub 2002.
347. Thomas D, Cortes, J, Garcia-Manero G, Faderl S, O'Brien S, Pierce S, Verstovsek S, Giles F, Andreeff M, Kornblau S, Letvak L, Kantarjian HM. Minimal residual disease (MRD) after Hyper-CVAD and Imatinib mesylate (ST1571) for Philadelphia (Ph) positive adult acute lymphocyte leukemia (ALL). Blood 11:764a, 2002. e-Pub 2002.
348. Kornblau SM, Qui YH, Womble MF, Cade JS, Jackson CE, Andreeff M. Patterns of expression of apoptosis regulating proteins in survivor cells from AML patients may predict response to therapy. Blood 11:329a, 2002. e-Pub 2002.
349. Swaby R, Kornblau SM. Retrospective Study to Evaluate the Economic Impact of Anemia. ASCO 21:265b, 2002. e-Pub 2002.
350. Kornblau S, Qui YH, Cade JS, Womble M. How comparable are protein level measurements obtained by flow cytometry laser scanning cytometry and western blotting?. Blood 11:330a, 2002. e-Pub 2002.
351. Cortes, J, Talpaz M, O'Brien S, Giles F, Kornblau S, Andreeff M, Rios MB, Kantarjian HM. Significance of lack of early cytogenetics (GC) response after therapy with Imatinib mesylate in relation to later achievement of major or complete CG response in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML). Blood 11:787a, 2002. e-Pub 2002.
352. Kornblau SM, Womble MF, Qui YH, Cade JS, Thomas D, Cortes J, Garcia-Manero G, Jackson CE, Andreeff M. A prospective study of apoptosis related proteins BCL2, Bax, PKC, ERK2, pERK in AML. Blood 11:329a, 2002. e-Pub 2002.
353. Kornblau SM, Millela M, Ball G, Y-H Q, Ruvolo P, Estrov Z, Beran M, Kantarjian HM, May WS, Andreeff M. ERK2 and Phospho-ERK2 are Prognostic for Survival in AML and Complement the Prognostic Impact of Bax and BCL-2. Blood 98(11):716a, 2001. e-Pub 2001.
354. Thomas D, Cortes JE, Giles FJ, O'Brien SM, Faderl S, Koller CA, Beran M, Issa JP, Garcia-Manero G, Estey EH, Pierce SA, Andreeff M, Kornblau SM, Keating MJ, Kantarjian HM. The Modified Hyper-CVAD Regimen in Newly Diagnosed Adult Acute Lympoblastic Leukemia (ALL). Blood 98(11):590a, 2001. e-Pub 2001.
355. Andreeff M, McQueen T, Edwards K, Cortes JE, Giles FJ, Estey EH, Konopleva M, Kornblau SM. Caspase Independent Cell Death in AML: An In Vivo Study in Patients Undergoing Chemotherapy. Blood 98(11):208b, 2001. e-Pub 2001.
356. Carter B, Milella M, Kornblau SM, Schober W, Tsao T, Contreras P, Reed J, Andreeff M. Expression and Regulation of XIAP in Acute Myeloid Leukemia by MAPK and PI3K Signaling. Blood 98(11):761a, 2001. e-Pub 2001.
357. Giles FJ, Thomas D, Cortes JE, Garcia-Manero G, Kornblau SM, Waddelow T, Kantarjian HM, Estey EH. An Ursodiol and Methylprednisone (MP) Regimen Does not Reduce Mylotarg-Associated Hepatic Veno-Occlusive Disease (VOD) in Patients with Acute Myeloid Leukemia (AML) not Receiving Stem Cell Transplantation (SCT). Blood 98(11):721a, 2001. e-Pub 2001.
358. Kantarjian HM, Cortes JE, O'Brien SM, Faderl S, Thomas D, Giles FJ, Garcia-Manero G, Albitar M, Andreeff M, Kornblau SM, Rios MB, Shan J, Beran M, Koller CA, Resta D, Capdeville R, Estey EH, Keating MJ, Freireich EJ, Talpaz M. Results of Imatinib Mesylate (STI571) in Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+CML-CP) Post Interferon Alpha (IFN) Failure. Blood 98(11):206b, 2001. e-Pub 2001.
359. Thomas D, O'Brien SM, Cortes JE, Faderl S, Fayad L, Garcia-Manero G, Wierda W, Verstovsek S, Kornblau SM, Pierce SA, Kantarjian HM, Keating MJ. Treatment of Splenic Lymphoma with Villous Lymphocytes (SLVL) and Marginal Zone Lymphomas (MZL) with Single Agent Rituximab. Blood 98(11):134a, 2001. e-Pub 2001.
360. Milella M, Estrov Z, Kornblau SM, Konopleva M, Tari A, Carter B, Schober W, Harris D, Leysath C, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic Induction of Apoptosis by Simultaneous Disruption of the Bcl-2 and MEK/MAPK Pathways in Acute Myelogenous Leukemia. Blood 98(11):840a, 2001. e-Pub 2001.
361. Kornblau SM, Y-H Q. Expression of Apoptosis and Cell Cycle Regulating Genes in "Survivor Cells" from AML Patients. Blood 98(11):92a, 2001. e-Pub 2001.
362. Garcia-Manero G, Daniel J, Pierce SA, Kornblau SM, Kantarjian HM, Jean-Pierre I. CpG island methylation profile in acute lymphocytic leukemia (all). Blood 96(11):102a, 2000. e-Pub 2000.
363. Shimoni A, Anderlini P, Andersson B, Andreeff M, Braunschweig I, Claxton DF, Cohen A, Donato M, Estey EH, Gajewski J, Khouri I, Korbling M, Kornblau SM, Molldrem J, Ueno NT, Champlin RE, Giralt S. Allogeneic transplantation for leukemia in patients older then 60 years: age should not exclude treatment with non-myeloablative regimens. Blood 94(10 Supp 1):710a, 1999. e-Pub 1999.
364. Konopleva M, Shourong Z, Zhong X, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis: molecules and mechanisms. Drug Resistance in Leukemia and Lymphoma III(24):217-36, 1999. e-Pub 1999.
365. Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 16(3):882-9, 1998. e-Pub 1998. PMID: 9508169.
366. Andreeff M, Zhao S, Konopleva M, Xie Z, Zhang X, Snell V, McQueen T, Jiang S, Weidner D, Estey EH, Thall PF, Sanchez-Williams G, Kornblau SM, Reed JC. The role of bcl-2 family genes in acute myeloid leukemia (AML): Therapeutic implications. Can Res 39:572, 1998. e-Pub 1998.
367. Kornblau SM, Marini FC. Murine suicidal lymphocytes produced by retroviral transduction survive transplantation, cause GVHD and respond to ganciclovir administration. Can Res 39:614, 1998. e-Pub 1998.
368. Andreeff M, Zhao S, Konopleva M, Xie Z, Zhang X, Snell V, Jiang S, K-O K, Weidner D, Estey EH, Kornblau SM, Reed JC. Regulation of apoptosis in normal hematopoiesis and myeloid leukemias. International Society for Analytical Cytology, 1997. e-Pub 1997.
369. Kantarjian HM, O'Brien SM, Keating MJ, Estey EH, Beran M, Koller CA, Kornblau SM, M-B R, Freireich EJ, Talpaz M. Interferon alpha (IFN-) and low-dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) 16(13a), 1997. e-Pub 1997.
370. Marini FC, Snell V, Lu J, Przepiorka D, Kornblau SM. Variable changes in lymphocyte subset composition (LSC) occur during production of human suicidal lymphocytes - implications for clinical trials. Blood, 1997. e-Pub 1997.
371. O'Brien SM, Kantarjian HM, Beran M, Robertson LE, Freireich EJ, Kornblau SM, Koller CA, Estey EH, Lerner S, Keating MJ. Fludarabine (FAMP) and mitoxantrone therapy in chronic lymphocytic leukemia (CLL). Blood 88, 1996. e-Pub 1996.
372. Kantarjian HM, O'Brien SM, Beran M, Giralt S, Estey EH, Koller CA, Kornblau SM, Andreeff M, de Vos D, Keating MJ, Talpaz M. Results with decitabine, a hypomethylating agent, in the treatment of chronic myelogenous leukemia (CML) in accelerated or blastic phases. Blood 88, 1996. e-Pub 1996.
373. O'Brien SM, Kantarjian HM, Beran M, Freireich EJ, Kornblau SM, Koller CA, Lerner S, Gilbreath J, Keating MJ. Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL). Blood 88, 1996. e-Pub 1996.
374. Estey EH, Thall P, Pierce SA, Fayad L, Kornblau SM, Kantarjian HM, Keating MJ. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Blood 88, 1996. e-Pub 1996.
375. Deng G, Lane C, Kornblau SM, Goodacre A, Snell V, Andreeff M, Deisseroth AB. Bcl-2 and bcl-xl are expressed at higher levels in poor prognosis (monosomy 5 and monosomy 7) acute myeloid leukemia (AML) cells than in good prognosis [(inversion 16 and t(8;21)] AML cells. Cancer Res 37, 1996. e-Pub 1996.
376. Deng G, Lane C, Kornblau SM, Goodacre A, Snell V, Andreeff M, Deisseroth AB. Bcl-X long expression is higher in poor prognosis (monosomy 5 and monosomy 7) acute myelogenous leukemia (AML) cells than in good prognosis [inversion 16 and t(8;21)] AML cells 15, 1996. e-Pub 1996.
377. Kantarjian HM, O'Brien SM, Keating MJ, Beran M, Koller CA, Estey EH, Kornblau SM, Rios MB, Talpaz M. Hommoharringtonine (HHT) and low-dose cytosine arabinoside (ARA-C) combination therapy has significant activity in patients (PTS) with late phase Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood 88, 1996. e-Pub 1996.
378. Fleming R, Estey EH, Kantarjian HM, O'Brien SM, Keating MJ, Beran M, Kornblau SM, Freireich EJ, Andreeff M, Cortes JE, Vassilaki M, Turan A, Risser J, Luna M, Anaissie E. Invasive aspergillosis during induction therapy for acute leukemia: Predisposing and prognostic factors. Blood 88, 1996. e-Pub 1996.
379. Cortes JE, Kantarjian HM, O'Brien SM, Beran M, Estey EH, Koller CA, Andreeff M, Kornblau SM, Keating MJ, Freireich EJ, M: T. Suppression of clonal evolution in patients with Philadelphia chromosome (ph)-positive chronic myelogenous leukemia (CML) on interferon ALFA therapy (IFN-A) therapy. Blood 88, 1996. e-Pub 1996.
380. Estey EH, Beran M, Hayes K, Lovshe D, Kornblau SM, Pierce SA, Koller CA, O'Brien SM, Kantarjian HM, Andreeff M, Keating MJ, Freireich EJ. Cytogenetic (CG) and fluorescent in SITU hybridization (FISH) analysis on course 1 day 21 of chemotherapy (CT) for newly - diagnosed AML/MDS. Blood 88, 1996. e-Pub 1996.
381. Cortes JE, Kantarjian HM, O'Brien SM, Estey EH, Beran M, Koller CA, Kornblau SM, Keating MJ, Freireich EJ. High frequency of latino ethnic background among adults with adult acute lymphocytic leukemia (ALL). Blood 88, 1996. e-Pub 1996.
382. Fayad L, Kantarjian HM, O'Brien SM, Beran M, Koller CA, Kornblau SM, Andreeff M, Estey EH, Keating MJ, Freireich EJ. Significance of day 7 (D7) persistence of peripheral blasts (PBb)>0, and day 14 (D14) persistence of bone marrow blasts (BMb) >5% in adult acute lymphocytic leukemia (ALL) according to treatment intensity. Blood 88, 1996. e-Pub 1996.
383. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13(11):2827-34, 1995. e-Pub 1995. PMID: 7595745.
384. Zhang W, Kornblau SM, Hester J, Deisseroth AB. The induction of WAF1/Cip1 protein by p53 in myeloid leukemia cell line and uncoupled regulation by p53 in primary acute myelogenous leukemia cells. Cancer Res 36, 1995. e-Pub 1995.
385. Kornblau SM, Andreeff M, Beran M, Escudier S, Kantarjian HM, Koller CA, O'Brien SM. 2-CDA+ ara-C is ineffective therapy for relapsed or refractory AML in adults 14, 1995. e-Pub 1995.
386. Kornblau SM, Huh YO, Andreeff M. CD7 expression in acute myelogenous leukemia is not prognostic after adjusting for cytogenetics 13, 1994. e-Pub 1994.
387. Andreeff M, Drach J, Sanchez-Williams G, Zhao S, Kornblau SM, Escudier S, Tafuri A, Kantarjian HM, Deisseroth AB, Estey EH. Treatment with cytokine/chemotherapy combinations of poor prognosis and relapsed AML and MDS: Response, biological effects and monitoring of minimal disease 12:1019, 1993. e-Pub 1993.
388. Kornblau SM, Xu HJ, Smith TL, Beran M, Hester J, Benedict WF, Deisseroth AB. The level of the retinoblastoma protein predicts for response to therapy and survival in acute myelogenous leukemia. Cancer Res 34:1349, 1993. e-Pub 1993.
389. Andreeff M, Drach J, Sanchez-Williams G, Zhao S, Lui Y, Kornblau SM, Escudier S, Kantarjian HM, Deisseroth AB, Estey EH. Treatment with G-CSF, fludarabine and ARA-C (FLAG) or poor prognosis AML and MDS: response, biological effects and monitoring of minimal disease, 1993. e-Pub 1993.
390. Deisseroth AB, Kavanagh JJ, Hanania EG, Fu S, Kornblau SM, Estey EH, Talpaz M, Kantarjian HM, Claxton DF, Reading CL, Dixon DA, Anderson RW, Lopez-Berestein G, Holmes FA, Logothetis CJ, Andreeff M, Benedict WF. Gene Therapy: Chemoprotectin, imunoenhancement, and modification of tumor cells 45(2), 1993. e-Pub 1993.
391. Estey EH, Kantarjian HM, O'Brien SM, Feldman E, Andreeff M, Escudier S, Kornblau SM, McCulloch E, Freireich EJ, Keating MJ. Treatment of poor-prognosis newly-diagnosed (ND) AML or MDS with G-CSF prior to, during, and following fludarabine, and ARA-C (Flag). Blood:439, 1992. e-Pub 1992.
392. Robertson LE, Pugh W, Hirsch-Ginsberg C, Smith TL, O'Brien SM, Cork A, Escudier S, Kornblau SM, Koller CA, Kantarjian HM, Estey EH, McLaughlin P, Cabanillas F, Keating MJ. Richter's Syndrome. ASH:179, 1992. e-Pub 1992.
393. Hu GY, Kornblau SM, Zhang W, Deisseroth AB. Altered expression of the p53 and retinoblastoma antioncogenes in acute myelogenous leukemia. Clinical Residence 40(144A), 1992. e-Pub 1992.
394. Andreeff M, Drach J, Tafuri A, Estey EH, Escudier S, Sanchez-Williams G, Dunne C, Goodacre A, Pereira-Leahy M, Zhao S, Kornblau SM, Kantarjian HM, Mandelli F, Plunkett W, Deisseroth AB. Interleukin-3 (IL-3) before and during Idarubicin/Ara-C in acute myeloblastic leukemia (AML): Phase I clinical and laboratory study. Blood:435, 1992. e-Pub 1992.
395. Kornblau SM, H-J X, Beran M, Estey EH, Smith TL, Hester J, Benedict WF, Deisseroth AB. Low levels of the retinoblastoma protein confer poor prognosis at diagnosis in newly diagnosed acute myelogenous leukemia. ASH:1015, 1992. e-Pub 1992.

Book Chapters

1. Hoff F, van Dijk AD, Kornblau SM. Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns. In: Proteoforms, 2019.
2. Hoff FW, Lu Y, Kornblau SM. Antibody Screening. In: Adv Exp Med Biol. Adv Exp Med Biol, 149-163, 2019.
3. Lantos C, Kornblau SM, Qutub AA. Quantitative-Morphological and Cytological Analyses in Leukemia. In: Hematology - Latest Research and Clinical Advances, 2018.
4. Kornblau SM. The Use of "Omics" to Guide the Selection of Targeted Therapy. In: Targeted Therapy of acute Myeloid Leukemia. Springer, 27-43, 2014.
5. Kornblau SM, Coombes KR. Use of Reverse Phase Protein Microarrays to Study Protein Expression in Leukemia: Technical and Methodological Lessons Learned. In: Methods Mol Biol. Humana Press, 141-142, 2011.
6. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis: Molecules and Mechanisms. In: Adv Exp Med Biol, 217-36, 1999.
7. Khouri I, Kantarjian HM, Talpaz M, Claxton D, Kornblau SM, Deisseroth AB. Molecular Diagnosis and Therapy of Hematopoietic Neoplasms. In: "The Molecular Basis of Cancer". W.B. Saunders, 1995.
8. Kornblau SM. Protein expression in acute leukemia; evaluation of disease- and age-specific expression patterns. In: Proteoforms.

Books (edited and written)

1. Kornblau SM. Molecular Biology, 2011.

Letters to the Editor

1. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109: 2660-2664, 2024.
2. Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase. Haematologica 107: 292-297, 2022.
3. Kornblau SM, Andreeff M, Estey EH, Kantarjian HM. Letter to Roar of the Crowd. Texas Monthly, 1997.
4. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 88: 756, 1996.